

**STIC-ILL**

---

**Fr m:** Wessendorf, Theresa  
**Sent:** Monday, June 25, 2001 2:52 PM  
**To:** STIC-ILL  
**Subject:** 09/408,578

OR 189. V82  
NPL  
Adams  
N

Please forward:  
Vaccine (1997), 15(14), 1551-1557.  
Txs.  
T. Wessendorf  
Art Unit 1627  
Mailrm. 3B01  
308-3967

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Terms	Documents
l3 and (multiple adj3 antigen)	0

**Database:**

[US Patents Full-Text Database](#)  
[US Pre-Grant Publication Full-Text Database](#)  
[JPO Abstracts Database](#)  
[EPO Abstracts Database](#)  
[Derwent World Patents Index](#)  
[IBM Technical Disclosure Bulletins](#)

**Refine Search:**

l3 and (multiple adj3 antigen)

[Clear](#)**Search History****Today's Date: 6/25/2001**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT	l3 and (multiple adj3 antigen)	0	<a href="#">L12</a>
USPT	l3 and (multiple adj3 antigen adj3 system)	0	<a href="#">L11</a>
USPT	l3 and (ligand adj3 presentation adj3 assembly)	0	<a href="#">L10</a>
USPT	l1 and (ligand adj3 presentation adj3 assembly)	0	<a href="#">L9</a>
USPT	l1 and (multiple adj3 antigen)	22	<a href="#">L8</a>
TDBD	borrelia adj5 burgdorferi	0	<a href="#">L7</a>
PGPB	borrelia adj5 burgdorferi	0	<a href="#">L6</a>
EPAB	borrelia adj5 burgdorferi	70	<a href="#">L5</a>
JPAB	borrelia adj5 burgdorferi	5	<a href="#">L4</a>
DWPI	borrelia adj5 burgdorferi	119	<a href="#">L3</a>
DWPI	l1	0	<a href="#">L2</a>
USPT	borrelia adj5 burgdorferi	292	<a href="#">L1</a>

**STIC-Biotech/ChemLib**

---

**From:** Wessendorf, Theresa  
**Sent:** Monday, June 25, 2001 3:31 PM  
**To:** STIC-Biotech/ChemLib  
**Subject:** 09/408,578

Please search for Seq. ID. 1 with the terms multiple antigen or peptide system or ligand presenting assembly. Also, inventors' search.

Thank you  
T. Wessendorf  
Art Unit 1627  
Mailrm. 3B01  
308-3967

=> fil hcaplus  
 FILE 'HCAPLUS' ENTERED AT 18:32:40 ON 26 JUN 2001  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 26 Jun 2001 VOL 135 ISS 1  
 FILE LAST UPDATED: 25 Jun 2001 (20010625/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAPLUS now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=>

=>

=> d stat que l3  
 L1 83 SEA FILE=REGISTRY ABB=ON PLU=ON PVVAESPKKP/SQSP  
 L2 24 SEA FILE=HCAPLUS ABB=ON PLU=ON L1  
 L3 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L2 AND (MULTIPLE(W)ANTIGEN OR PEPTIDE(W)SYSTEM OR LIGAND)

=> d ibib abs hitrn l3 1-2

L3 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 2000:569091 HCAPLUS  
 DOCUMENT NUMBER: 133:265384  
 TITLE: **Ligand**-presenting assembly: a method for C- and N-terminal antigen presentation  
 AUTHOR(S): Holm, A.; Jorgensen, R. M.; Ostergaard, S.; Theisen, M.  
 CORPORATE SOURCE: Research Center for Medical Biotechnology, Chemistry Department, The Royal Veterinary and Agricultural University, Copenhagen, DK-1871, Den.  
 SOURCE: J. Pept. Res. (2000), 56(2), 105-113  
 CODEN: JPERFA; ISSN: 1397-002X  
 PUBLISHER: Munksgaard International Publishers Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Achiral dicarboxylic acids were coupled with 2 equiv. of the free .alpha.-amino groups of two fully side-chain protected peptide chains while these were still attached to a synthesis resin. Cleavage from the resin with simultaneous side-chain deprotection afforded two assembled peptide chains with free C-terminals. Suitable functionalization of the achiral dicarboxylic acid alternatively permitted continued peptide synthesis in a C to N orientation leading to a final peptide assembly

which, after cleavage from the resin, may have multiple N to C and C to N presentation of one or more epitopes.

IT 262859-56-3P

RL: ARG (Analytical reagent use); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)

(prepn. and application in ELISA)

IT 263013-02-1P

RL: BAC (Biological activity or effector, except adverse); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and immunogenicity of)

IT 262859-57-4P 262859-58-5P 262859-59-6P

263013-01-0P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

REFERENCE COUNT: 16

REFERENCE(S): (1) Aletras, A; J Peptide Protein Res 1995, V45, P488 HCAPLUS  
(2) Bhatnagar, P; J Med Chem 1996, V39, P3814 HCAPLUS  
(3) Brandt, L; J Immunol 1996, V157, P3527 HCAPLUS  
(5) Keah, H; J Peptide Res 1998, V51, P2 HCAPLUS  
(6) Kim, H; J Med Chem 1994, V37, P3373 HCAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:227676 HCAPLUS

DOCUMENT NUMBER: 132:250004

TITLE: **Ligand** presenting assembly (LPA), method of preparation and uses thereof

INVENTOR(S): Holm, Arne; Jorgensen, Rikke Malene; Ostergaard, Soren; Theisen, Michael

PATENT ASSIGNEE(S): Statens Serum Institut, Den.

SOURCE: PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000018791	A1	20000406	WO 1999-DK510	19990929
W:				
AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9960783	A1	20000417	AU 1999-60783	19990929
PRIORITY APPLN. INFO.:			DK 1998-1233	A 19980929
			WO 1999-DK510	W 19990929

OTHER SOURCE(S): MARPAT 132:250004

AB The present invention relates to a method for prep. a **Ligand** Presenting Assembly (LPA), an LPA, an immunol. compn. and a vaccine. The N-terminal of LPA is coupled to an achiral di, tri, or tetra-carboxylic acid so as to provide a construct having a ring structure. The invention further relates to a method for generating antibodies, a kit for use in diagnosis and use of an LPA for prep. a pharmaceutical compn.

IT 262859-56-3P, LPA-I 262859-57-4P, LPA-II

262859-58-5P, LPA-III 262859-59-6P, LPA-IV

263013-01-0P 263013-02-1P

RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(**ligand** presenting assembly comprising achiral carboxylic acid-modified antigen as vaccine for diagnosis of infections)

IT 199437-17-7, Pvvvaespkkp peptide+

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**ligand** presenting assembly comprising achiral carboxylic acid-modified antigen as vaccine for diagnosis of infections)

REFERENCE COUNT:

7

REFERENCE(S):

- (1) Anthony, G; WO 9402506 A 1994 HCAPLUS
  - (2) Golding Louise; WO 9832469 A 1998 HCAPLUS
  - (3) Harboe, M; INFECTION AND IMMUNITY 1998, V66(2), P717 HCAPLUS
  - (4) Peluso, S; TETRAHEDRON 1997, V53(21), P7231 HCAPLUS
  - (5) Statens Seruminstitut; WO 9742221 A 1997 HCAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; d stat que 14

L1 83 SEA FILE=REGISTRY ABB=ON PLU=ON PVVAESPKKP/SQSP  
 L2 24 SEA FILE=HCAPLUS ABB=ON PLU=ON L1  
 L3 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L2 AND (MULTIPLE(W)ANTIGEN OR PEPTIDE(W)SYSTEM OR LIGAND)  
 L4 12 SEA FILE=HCAPLUS ABB=ON PLU=ON (L1 AND (ANTIGEN? OR ASSEMBL? OR LPA?)) NOT L3

=&gt;

=&gt;

=&gt; d ibib abs hitrn 14 1-12

L4 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:190694 HCAPLUS

DOCUMENT NUMBER: 134:339287

TITLE: Selection of continuous epitope sequences and their incorporation into poly(ethylene glycol)-peptide conjugates for use in serodiagnostic immunoassays: application to Lyme disease

AUTHOR(S): Qiu, Bo; Brunner, Michael; Zhang, Guobao; Sigal, Leonard; Stein, Stanley

CORPORATE SOURCE: Center for Advanced Biotechnology and Medicine, Piscataway, NJ, 08854, USA

SOURCE: Biopolymers (2001), 55(4), 319-333  
 CODEN: BIPMAA; ISSN: 0006-3525

PUBLISHER: John Wiley &amp; Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Continuous epitope sequences were selected from immunogenic Bb proteins by epitope mapping. The identified epitope sequences were synthesized by solid phase peptide synthesis and purified by high performance liq. chromatog. Each epitope was conjugated individually to a multifunctional poly(ethylene glycol) (PEG) carrier. The result PEG-peptide conjugates were used as **antigens** in ELISA for diagnosis of Lyme disease.

The results showed that the defined epitope peptides were Lyme disease specific and could be used in a format of PEG-peptide conjugate as the **antigen** to achieve improved sensitivity and specificity.

IT 338741-11-0D, polyethylene glycol conjugates

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)  
(polyethylene glycol-peptide conjugates for use in serodiagnostic  
immunoassay of Lyme disease)

REFERENCE COUNT: 26  
REFERENCE(S): (3) Cartwright, G; J Immunol Methods 1995, V179, P31  
HCAPLUS  
(5) Fikrig, E; Proc Natl Acad Sci USA 1993, V90, P183  
HCAPLUS  
(6) Geysen, H; Proc Natl Acad Sci USA 1984, V81, P3998  
HCAPLUS  
(8) Kaiser, E; Anal Biochem 1970, V34, P595 HCAPLUS  
(9) Mathiesen, M; Infect Immun 1998, V66(9), P4073  
HCAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 2000:98788 HCAPLUS  
DOCUMENT NUMBER: 132:150602  
TITLE: Uses of borreliacidal epitopes of Borrelia burgdorferi  
outer surface protein C (OspC) in vaccines  
INVENTOR(S): Callister, Steven N.; Lovrich, Steven D.; Schell,  
Ronald F.; Jobe, Dean A.  
PATENT ASSIGNEE(S): Gundersen Lutheran Medical Foundation, Inc., USA  
SOURCE: PCT Int. Appl., 51 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006745	A1	20000210	WO 1999-US17270	19990730
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9953282	A1	20000221	AU 1999-53282	19990730
US 6210676	B1	20010403	US 1999-364083	19990730
EP 1100922	A1	20010523	EP 1999-938897	19990730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 2001000412	A	20010329	NO 2001-412	20010124
PRIORITY APPLN. INFO.:				
			US 1998-94955	P 19980731
			WO 1999-US17270	W 19990730
AB	An epitope of the outer membrane protein C (OspC) of Borrelia burgdorferi is described for the prevention, treatment and early diagnosis of Lyme disease in humans and other animals. This invention also relates to a screening method detecting anti-OspC borreliacidal antibody activity, and antibodies reacting with a protein fragment encoded by a DraI-SmaI DNA fragment of the OspC gene. The OspC gene was cloned and deletion anal. was used to identify the region of the gene encoding a borreliacidal epitope. Borreliacidal antibodies to OspC were found in the serum of early Lyme disease patients and absorption of the serum with the OspC epitope lowered the borreliacidal activity 32-512-fold.			
IT	257260-46-1			
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); PRP (Properties); THU (Therapeutic use); BIOL (Biological				

study); PROC (Process); USES (Uses)  
 (amino acid sequence; uses of borreliacidal epitopes of *Borrelia burgdorferi* outer surface protein C (OspC) in vaccines)

IT 257289-49-9

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (epitope of OspC gene product of *Borrelia*; uses of borreliacidal epitopes of *Borrelia burgdorferi* outer surface protein C (OspC) in vaccines)

REFERENCE COUNT:

2

REFERENCE(S):

- (1) Immuno Ag; WO 9425596 A 1994 HCAPLUS
- (2) Statens Seruminstitut; WO 9742221 A 1997 HCAPLUS

L4 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:809492 HCAPLUS

DOCUMENT NUMBER: 132:148850

TITLE: Genetic analysis of *Borrelia garinii* OspA serotype 4 strains associated with neuroborreliosis: evidence for extensive genetic homogeneity

AUTHOR(S): Marconi, R. T.; Hohenberger, S.; Jauris-Heipke, S.; Schulte-Spechtel, U.; LaVoie, C. P.; Rossler, D.; Wilske, B.

CORPORATE SOURCE: Medical College of Virginia at Virginia, Commonwealth University, Richmond, VA, 23298-0678, USA

SOURCE: J. Clin. Microbiol. (1999), 37(12), 3965-3970

CODEN: JCMIDW; ISSN: 0095-1137

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Infection with *Borrelia garinii* outer surface protein (Osp) A serotype 4 strains has been correlated with the development of neuroborreliosis in Lyme borreliosis patients in Europe. OspA serotype 4 isolates have been recovered primarily from human cerebrospinal fluid, suggesting a tropism for this environment. Previous studies with monoclonal antibodies directed against OspA and OspC demonstrated that OspA serotype 4 strains are **antigenically** closely related. In view of the pronounced **antigenic** and genetic variability that has been noted in the Osps of other *Borrelia* isolates, we sought to det. if OspA serotype 4 strains represent a recently emerged clonal lineage of *B. garinii*. Toward this goal, a representative group of OspA serotype 4 strains was analyzed for traits that typically exhibit hypervariability among isolates that cause Lyme borreliosis. The following criteria were assessed: (1) ospC sequences, (2) plasmid compn., (3) genomic restriction fragment length polymorphism (RFLP) patterns, and (4) the RFLP patterns of the upstream homol. box (UHB) element which flanks members of the UHB gene family at their 5' end. Collectively, these analyses demonstrate genetic homogeneity, suggesting that OspA serotype 4 strains are a recently emerged clonal lineage with an apparent tropism for the central nervous system.

IT 169539-68-8, Protein (*Borrelia garinii* strain PTrob gene ospC outer surface)

RL: PRP (Properties)

(amino acid sequence; genetic anal. of *Borrelia garinii* OspA serotype 4 strains assocd. with neuroborreliosis: evidence for extensive genetic homogeneity)

REFERENCE COUNT: 63

REFERENCE(S):

- (2) Baranton, G; Int J Syst Bacteriol 1992, V42, P378 HCAPLUS
- (4) Barbour, A; J Bacteriol 1996, V178, P6635 HCAPLUS
- (5) Barbour, A; J Clin Microbiol 1988, V26, P475 HCAPLUS
- (7) Barbour, A; Science 1987, V237, P409 HCAPLUS



(8) Busch, U; J Clin Microbiol 1996, V34, P1072  
HCAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:659148 HCAPLUS  
DOCUMENT NUMBER: 131:285385  
TITLE: Method, **antigen** complex and kit for  
diagnosing Lyme borreliosis  
INVENTOR(S): Staffeldt, Schou Ole; Winther, Lars; Stender, Henrik  
PATENT ASSIGNEE(S): Dako A/S, Den.  
SOURCE: Eur. Pat. Appl., 23 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 949508	A1	19991013	EP 1999-610026	19990407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: DK 1998-516 19980408

AB A diagnostic method is disclosed which utilizes an **antigen** complex comprising a carrier to which is attached a plurality of Borrelia OspC peptides and optionally other Borrelia peptides. The **antigen** complex is used for detn. of IgM antibodies against B. burgdorferi sensu lato. The **antigen** complex comprises a sufficient no. of peptides having affinity for a relevant epitope on the IgM antibody to be detected to allow the **antigen** complex to bind to the IgM antibody without being removed during the washing step. The Borrelia flagellum is another important immunodominant **antigen**. The simultaneous detn. of antibodies against Borrelia OspC and flagellum is also disclosed. The method is particularly useful for diagnosing Lyme borreliosis in the early stages. An ELISA of human serum samples used **antigen** complexes contg. biotinylated flagella biotinylated OspC peptide and streptavidin-horseradish peroxidase conjugate.

IT 246219-51-2P 246219-52-3P

RL: ARG (Analytical reagent use); DEV (Device component use); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence, as Borrelia OspC peptide in **antigen** complex; method and **antigen** complex and kit for diagnosing Lyme borreliosis)

REFERENCE COUNT: 2

REFERENCE(S): (1) Hansen, K; JOURNAL OF CLINICAL MICROBIOLOGY 1991, V29(1), P166 MEDLINE  
(2) Seruminstitut, S; WO 9742221 A 1997 HCAPLUS

L4 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:804175 HCAPLUS  
DOCUMENT NUMBER: 128:85027  
TITLE: Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi  
AUTHOR(S): Fraser, Claire M.; Casjens, Sherwood; Huang, Wai Mun; Sutton, Granger G.; Clayton, Rebecca; Lathigra, Raju; White, Owen; Ketchum, Karen A.; Dodson, Robert; Hickey, Erin K.; Gwinn, Michelle; Dougherty, Brian; Tomb, Jean-Francois; Fleischmann, Robert D.; Richardson, Delwood; Peterson, Jeremy; Kerlavage, Anthony R.; Quackenbush, John; Salzberg, Steven;

Hanson, Mark; van Vugt, Rene; Palmer, Nanette; Adams, Mark D.; Gocayne, Jeannine; Weidman, Janice; Utterback, Teresa; Watthey, Larry; McDonald, Lisa; Artiach, Patricia; Bowman, Cheryl; Garland, Stacey; Fujii, Claire; Cotton, Matthew D.; Horst, Kurt; Roberts, Kevin; Hatch, Bonnie; Smith, Hamilton O.; Venter, J. Craig

CORPORATE SOURCE: Inst. Genomic Research, Rockville, MD, 20850, USA  
 SOURCE: Nature (London) (1997), 390(6660), 580-586  
 CODEN: NATUAS; ISSN: 0028-0836  
 PUBLISHER: Macmillan Magazines  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The genome of the bacterium *Borrelia burgdorferi* B31, the etiol. agent of Lyme disease, contains a linear chromosome of 910,725 base pairs and at least 17 linear and circular plasmids with a combined size of more than 533,000 base pairs. The chromosome contains 853 genes encoding a basic set of proteins for DNA replication, transcription, translation, solute transport and energy metab., but, like *Mycoplasma genitalium*, it contains no genes for cellular biosynthetic reactions. Because *B. burgdorferi* and *M. genitalium* are distantly related eubacteria, we suggest that their limited metabolic capacities reflect convergent evolution by gene loss from more metabolically competent progenitors. Of 430 genes on 11 plasmids, most have no known biol. function; 39% of plasmid genes are paralogs that form 47 gene families. The biol. significance of the multiple plasmid-encoded genes is not clear, although they may be involved in **antigenic** variation or immune evasion.

IT **148847-97-6**, Protein (*Borrelia burgdorferi* strain ATCC 35210 clone pUC-B31/ospCL+ gene ospC precursor reduced)  
 RL: PRP (Properties)  
 (amino acid sequence; genomic sequence of a Lyme disease spirochaete, *Borrelia burgdorferi*)

L4 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:806461 HCAPLUS  
 DOCUMENT NUMBER: 123:220266  
 TITLE: Diagnosis of early Lyme disease by assay of the OspC protein or the gene  
 INVENTOR(S): Padula, Steven J.  
 PATENT ASSIGNEE(S): University of Connecticut, USA  
 SOURCE: PCT Int. Appl., 56 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9514781	A2	19950601	WO 1994-US13540	19941122
WO 9514781	A3	19950622		
W: AU, CA, JP, RU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5620862	A	19970415	US 1993-158353	19931124
CA 2177356	AA	19950601	CA 1994-2177356	19941122
AU 9511864	A1	19950613	AU 1995-11864	19941122
PRIORITY APPLN. INFO.:			US 1993-158353	19931124
			WO 1994-US13540	19941122

AB The *Borrelia burgdorferi* sensu stricto outer surface protein C and the gene encoding are used in the early diagnosis of Lyme disease. Purified and recombinant forms of a 23 kDa protein from a Connecticut isolate of *B. burgdorferi* are described. The 23kDa protein, referred to as p23 or OspC, can be used for immunodiagnostic assays for detection of early Lyme

disease. The protein and the gene can be used to prevent Lyme disease and to diagnose or detect *B. burgdorferi* in human or animal tissues or body fluids. Antibodies specific for the protein can also be generated and the protein may be used as an **antigen** in vaccines (no data). Clin. studies of diagnostic immunoassays are reported.

IT **146990-46-7**, Protein pC (*Borrelia burgdorferi* strain PKo gene pc precursor reduced) **148847-97-6**, Protein (*Borrelia burgdorferi* strain ATCC 35210 clone pUC-B31/ospCL+ gene ospC precursor reduced)  
 RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (amino acid sequence; diagnosis of early Lyme disease by assay of OspC protein or gene)

L4 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:758781 HCAPLUS

DOCUMENT NUMBER: 123:283622

TITLE: Fusion proteins of **antigenic** polypeptides of *Borrelia* for diagnostic and therapeutic use and their manufacture

INVENTOR(S): Dunn, John J.; Luft, Benjamin J.

PATENT ASSIGNEE(S): Associated Universities, Inc., USA

SOURCE: PCT Int. Appl., 199 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9512676	A1	19950511	WO 1994-US12352	19941027
W: AU, CA, FI, JP, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6248562	B1	20010619	US 1994-235836	19940429
AU 9481274	A1	19950523	AU 1994-81274	19941027
EP 726955	A1	19960821	EP 1995-900453	19941027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:		US 1993-148191	A	19931101
		US 1994-235836	A	19940429
		WO 1994-US12352	W	19941027

AB Chimeric genes for fusion proteins of at least two **antigenic** polypeptides from one or more species of *Borrelia* are described for manuf. of the **antigens** for vaccines against borreliosis. The proteins are also useful as immunodiagnostic reagents. The **antigenic** peptides may be from the same or different larger proteins and may be from different species. The outer surface protein OspA was purified and **antigenic** domains mapped with monoclonal antibodies. A immunol. important hypervariable region of OspA was identified. The cloning of genes for a no. of outer surface proteins and their use in the construction of chimeric genes is described.

IT **167360-66-9 167360-68-1 167360-70-5**

**167360-72-7**

RL: BOC (Biological occurrence); PRP (Properties); THU (Therapeutic use);

BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(amino acid sequence; fusion proteins of **antigenic**

polypeptides of *Borrelia* for diagnostic and therapeutic use and their manuf.)

IT **167360-88-5P 167360-90-9P 167361-02-6P**

RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; fusion proteins of **antigenic**

polypeptides of *Borrelia* for diagnostic and therapeutic use and their manuf.)

L4 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1995:397240 HCAPLUS  
 DOCUMENT NUMBER: 122:185342  
 TITLE: Immunogenic formulation of OspC **antigen**  
 vaccines for the prevention and treatment of Lyme  
 disease and recombinant methods for the preparation of  
 such **antigens**  
 INVENTOR(S): Livey, Ian; Crowe, Brian; Dorner, Friedrich  
 PATENT ASSIGNEE(S): Immuno AG, Austria  
 SOURCE: PCT Int. Appl., 104 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9425596	A2	19941110	WO 1994-EP1365	19940429
WO 9425596	A3	19941222		
W: AT, AU, CA, CZ, FI, HU, JP, NO, PL, RU, SI, SK, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9467229	A1	19941121	AU 1994-67229	19940429
AU 683260	B2	19971106		
EP 701612	A1	19960320	EP 1994-915562	19940429
EP 701612	B1	19980121		
R: AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, LI, NL, PT, SE				
HU 72923	A2	19960628	HU 1995-2002	19940429
HU 217024	B	19991129		
JP 08509371	T2	19961008	JP 1994-523899	19940429
AT 162550	E	19980215	AT 1994-915562	19940429
ES 2114687	T3	19980601	ES 1994-915562	19940429
SK 279968	B6	19990611	SK 1995-1341	19940429
PL 178775	B1	20000630	PL 1994-311301	19940429
FI 9505150	A	19951228	FI 1995-5150	19951027
NO 9504318	A	19951229	NO 1995-4318	19951027
PRIORITY APPLN. INFO.:			US 1993-53863	A 19930429
			WO 1994-EP1365	W 19940429

AB Immunogenic formulations for protection against Lyme disease, use of the formulations for vaccination, OspC **antigens**, and a method for manuf. of OspC **antigens** with recombinant cells are claimed. An approach to Borrelia vaccine formulation taking into account serol., genotypic and epidemiol. information by which OspC proteins from different strains of B. burgdorferi are grouped together is described. OspC **antigens** are chosen in order to constitute a representative sample of such groupings, so that the resulting vaccine provides the greatest cross-protectivity with the fewest no. of **antigens**. Common membrane **antigen** type typing of B. burgdorferi strains, development of an OspC serovar typing scheme, RFLP anal. of ospC heterogeneity, and PCR amplification and sequencing of different alleles of the ospC gene and cluster anal. of the deduced amino acid sequences was described. Addnl., epitope mapping of anti-OspC monoclonal antibodies, cross-protection studies in gerbils, and frequency of occurrence geog. distribution of various families of OspC protein assocd. with human disease were presented. OspC **antigens** were produced with recombinant Pichia pastoris.

IT 146990-47-8, Protein pC (Borrelia burgdorferi strain PKo gene pc reduced) 161630-08-6, Protein (Borrelia strain IP2 gene ospC) 161630-11-1, Protein (Borrelia strain 297 gene ospC) 161630-15-5, Protein (Borrelia strain ACA1 gene ospC) 161630-16-6, Protein (Borrelia strain H9 gene ospC) 161630-18-8

RL: PRP (Properties)  
 (amino acid sequence; immunogenic formulation of OspC **antigen**  
 vaccines for the prevention and treatment of Lyme disease and  
 recombinant methods for the prepn. of such **antigens**)

L4 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:267636 HCAPLUS  
 DOCUMENT NUMBER: 120:267636  
 TITLE: Molecular characterization and expression of p23  
 (OspC) from a North American strain of *Borrelia burgdorferi*  
 AUTHOR(S): Padula, Steven J.; Sampieri, Alicia; Dias, Feliciano;  
 Szczepanski, Andrew; Ryan, Raymond W.  
 CORPORATE SOURCE: Health Cent., Univ. Connecticut, Farmington, CT,  
 06030-1310, USA  
 SOURCE: Infect. Immun. (1993), 61(12), 5097-105  
 CODEN: INFIBR; ISSN: 0019-9567  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The authors have found that sera from patients with early stages of Lyme disease contain predominant IgM reactivity to a major 23-kDa protein (p23) from *Borrelia burgdorferi* 2591 isolated in Connecticut. To characterize this immunodominant **antigen**, the authors cloned and sequenced p23 and found it to be 83% identical by nucleotide sequence and 75% identical by amino acid sequence to pC (recently renamed OspC), an abundantly expressed protein on the outer surface of PKo, a European strain of *B. burgdorferi* (B. Wilske, et al, 1993). Immunoelectron microscopy localized p23 to the outer membrane, confirming that p23 is the strain 2591 homolog of OspC. The North American strain B31, commonly used in serol. assays for Lyme disease, does not express OspC. Northern (RNA) blot anal. detected low levels of ospC mRNA in B31, and DNA sequencing of the ospC gene from B31 revealed a 54-bp deletion in the upstream regulatory region, possibly accounting for the low transcriptional activity of ospC. The ospC coding region from B31 was cloned and antibody-reactive OspC was expressed in *Escherichia coli*. An IgM ELISA using recombinant OspC as the target **antigen** shows promise for the serodiagnosis of early stages of Lyme disease.

IT 148847-97-6, Protein p23 (*Borrelia burgdorferi* strain 2591)  
 RL: PRP (Properties)  
 (amino acid sequence of)

L4 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1993:510285 HCAPLUS  
 DOCUMENT NUMBER: 119:110285  
 TITLE: Genetic heterogeneity of the genes coding for the  
 outer surface protein C (OspC) and the flagellin of  
*Borrelia burgdorferi*  
 AUTHOR(S): Jauris-Heipke, S.; Fuchs, R.; Motz, M.; Preac-Mursic,  
 V.; Schwab, E.; Soutschek, E.; Will, G.; Wilske, B.  
 CORPORATE SOURCE: Max von Pettenkofer Inst., Munich, W-8000/2, Germany  
 SOURCE: Med. Microbiol. Immunol. (1993), 182(1), 37-50  
 CODEN: MMIYAO; ISSN: 0300-8584  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The ospC gene coding for the outer surface protein OspC and the fla gene coding for the flagellin have been investigated in three different *Borrelia burgdorferi* sensu lato strains. These strains (the North American strain B31 and the European strains PKo and PBi) derive from various biol. sources (*Ixodes dammini*, human skin and human CSF) and belong to 3 different *B. burgdorferi* OspA serotypes and genospecies (OspA serotype 1, *B. burgdorferi* sensu stricto; OspA serotype 2, group VS461 and OspA serotype 4, *B. garinii*, resp.). The ospC and fla genes of the resp. strains have been amplified by polymerase chain reaction, cloned in pUC8

and sequenced. The fla as well as the ospC gene were different among the 3 strains investigated. In general the fla genes are more conserved than the ospC genes. The fla genes have the same length of 1008 nucleotides coding for proteins of 336 amino acids, whereas the ospC genes differ in length. The ospC genes of strains B31, PKo, and PBi have 630, 636, and 621 nucleotides encoding proteins of 210, 212, and 207 amino acids, resp. The ospC genes exhibit sequence identities between 70% and 74% among each other; sequence identities of the fla genes are in the range 96-97%. The ospC genes could be expressed in *Escherichia coli* to obtain proteins with and without leader peptides. The expression of the fla gene and an internal gene fragment resulted in the complete flagellin protein and a truncated protein (amino acids 129-251). The different ospC and fla gene products were immunoreactive with monoclonal antibodies and human sera and, thus, enlarge the spectrum of recombinant **antigens** to improve antibody detection in patients with Lyme borreliosis.

IT **148847-97-6**, Protein C (*Borrelia burgdorferi* strain B31 pUC-B31/ospCL+ gene ospC precursor) **148847-98-7**, Protein C (*Borrelia burgdorferi* strain PBi pUC-PBi/ospCL+ gene ospC precursor)  
 RL: PRP (Properties)  
 (amino acid sequence and immunoreactivity of)

L4 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1993:186033 HCAPLUS  
 DOCUMENT NUMBER: 118:186033  
 TITLE: Molecular analysis and expression of a *Borrelia burgdorferi* gene encoding a 22kDa protein (pC) in *Escherichia coli*  
 AUTHOR(S): Fuchs, R.; Jauris, S.; Lottspeich, F.; Preac-Mursic, V.; Wilske, B.; Soutschek, E.  
 CORPORATE SOURCE: Max von Pettenkofer-Inst., Univ. Munich, Munich, 8000/2, Germany  
 SOURCE: Mol. Microbiol. (1992), 6(4), 503-9  
 CODEN: MOMIEE; ISSN: 0950-382X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The authors describe the cloning and expression of the pc gene which encodes a major immunodominant protein of *B. burgdorferi*, the causative agent of Lyme borreliosis. The pC protein was purified from lysates of *B. burgdorferi* strain PKo. After tryptic digestion of the pC protein the resulting oligopeptides were applied to a gas-phase sequenator to obtain partial amino acid sequences. The deduced oligonucleotides were used as hybridization probes. After Southern blotting, a reactive band in the 3-kb range of PstI-digested genomic DNA was detected. The insertion of these fragments into pUC vectors finally resulted in pc-pos. *E. coli* clones. The gene (encoding a protein with 212 amino acids) was expressed in *E. coli* with varying deletions at the 5' end. A sequence comparison with other outer membrane proteins of *B. burgdorferi* indicates processing of pC that is similar to that of lipoproteins.

IT **146990-46-7**  
 RL: PRP (Properties)  
 (amino acid sequence of, complete)

L4 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1992:82044 HCAPLUS  
 DOCUMENT NUMBER: 116:82044  
 TITLE: Immunologically active proteins from *Borrelia burgdorferi*, related test kits, vaccines, and monoclonal antibodies  
 INVENTOR(S): Fuchs, Renate; Wilske, Bettina; Preac-Mursic, Vera; Motz, Manfred; Soutschek, Erwin  
 PATENT ASSIGNEE(S): Mikrogen Molekularbiologische Entwicklungs-G.m.b.H., Germany  
 SOURCE: PCT Int. Appl., 68 pp.

DOCUMENT TYPE: CODEN: PIXXD2  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: 2 German  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9109870	A1	19910711	WO 1990-EP2282	19901221
W: AU, CA, FI, JP, NO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
DE 3942728	C1	19910523	DE 1989-3942728	19891222
DE 4018988	A1	19911219	DE 1990-4018988	19900613
DE 4018988	C2	19990708		
AU 9170586	A1	19910724	AU 1991-70586	19901221
EP 506868	A1	19921007	EP 1991-902687	19901221
EP 506868	B1	19960717		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
US 6248538	B1	20010619	US 1994-209603	19940310
PRIORITY APPLN. INFO.:				
			DE 1989-3942728 A	19891222
			DE 1990-4018988 A	19900613
			WO 1990-EP2282 A	19901221
			US 1992-862535 A1	19920619

AB Immunol. active proteins of *B. burgdorferi* were prepd. in microorganisms by genetic engineering. The specific DNA sequences were selected from a *B. burgdorferi* gene bank, using suitable search methods, or represented directly by DNA amplification with selected hybridization samples and placed under the control of inducible promoters, such as the lac promoter. These proteins can be used to produce specific and sensitive diagnostic test kits. Selective combination of the immunol. active proteins makes accurate diagnosis possible. Monoclonal antibodies were produced which can be used as reagents for the detection of the bacteria directly from test samples or after cultivation. The proteins can be used to distinguish *Borrelia* from *Treponema* infections. The p41 flagellin of *B. burgdorferi* was cloned, sequenced, and used in an ELISA for detection of antibodies in serum.

IT **138756-96-4**, Protein pC (*Borrelia burgdorferi* clone pDS1PC5 22-kilodalton reduced)  
 RL: PROC (Process)  
 (amino acid sequence and mol. cloning of, for diagnosis and vaccines)

=>  
 =>

=> select hit rn 13 1-2  
 E1 THROUGH E7 ASSIGNED

=> select hit rn 14 1-12  
 E8 THROUGH E30 ASSIGNED

=> fil reg  
 FILE 'REGISTRY' ENTERED AT 18:36:38 ON 26 JUN 2001  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 25 JUN 2001 HIGHEST RN 343304-93-8  
 DICTIONARY FILE UPDATES: 25 JUN 2001 HIGHEST RN 343304-93-8

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when





SEQ 1 PVVAESPKKP

HITS AT: 1-10

REFERENCE 1: 133:265384

REFERENCE 2: 132:250004

L6 ANSWER 3 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN 263013-01-0 REGISTRY

CN L-Proline, N2,N6-bis(L-tyrosyl-L-glutaminyglycyl-L-valyl-L-glutaminy-L-glutaminy-L-lysyl-L-tryptophyl-L-.alpha.-aspartyl-L-alanyl-L-threonyl-L-alanyl-L-threonyl-L-.alpha.-glutamyl-L-leucyl-L-asparaginy-L-asparaginy-L-alanyl-L-leucyl-L-glutaminy)-L-lysyl-3-aminopentanedioylbis[L-prolyl-L-valyl-L-valyl-L-alanyl-L-.alpha.-glutamyl-L-seryl-L-prolyl-L-lysyl-L-lysyl-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 37: PN: WO0018791 PAGE: 81 claimed sequence

CN LPA-V

NTE multichain

type	location	description
bridge	Lys-21 - Gln-20'	amide bridge
bridge	Oaa-22 - Pro-1''	amide bridge
uncommon	Oaa-22 -	-

SQL 62,32,20,10

RN 263013-01-0 REGISTRY

SEQ 1 YQGVQQKWDA TATELNALQ KXPVVAESPK KP

HITS AT: 23-32

SEQ 1 PVVAESPKKP

HITS AT: 1-10

REFERENCE 1: 133:265384

REFERENCE 2: 132:250004

L6 ANSWER 4 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN 262859-59-6 REGISTRY

CN L-Proline, L-lysyl-3-aminopentanedioylbis[L-prolyl-L-valyl-L-valyl-L-alanyl-L-.alpha.-glutamyl-L-seryl-L-prolyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 36: PN: WO0018791 PAGE: 80 claimed sequence

CN LPA-IV

NTE multichain

modified (modifications unspecified)

type	location	description
bridge	Pro-1 - Pro-1'	covalent bridge, dimer

SQL 20,10,10

RN 262859-59-6 REGISTRY

SEQ 1 PVVAESPKKP

HITS AT: 1-10

SEQ 1 PVVAESPKKP

=====

HITS AT: 1-10

REFERENCE 1: 133:265384

REFERENCE 2: 132:250004

L6 ANSWER 5 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN 262859-58-5 REGISTRY

CN L-Proline, 1,1'-(3-amino-1,5-dioxo-1,5-pentanediy1)bis[L-prolyl-L-valyl-L-valyl-L-alanyl-L-.alpha.-glutamyl-L-seryl-L-prolyl-L-lysyl-L-lysyl- (9CI)  
(CA INDEX NAME)

OTHER NAMES:

CN 35: PN: WO0018791 PAGE: 80 claimed sequence

CN LPA-III

NTE multichain

modified (modifications unspecified)

type	-----	location	-----	description
bridge		Pro-1	- Pro-1'	covalent bridge, dimer

SQL 20,10,10

RN 262859-58-5 REGISTRY

SEQ 1 PVVAESPKKP

=====

HITS AT: 1-10

SEQ 1 PVVAESPKKP

=====

HITS AT: 1-10

REFERENCE 1: 133:265384

REFERENCE 2: 132:250004

L6 ANSWER 6 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN 262859-57-4 REGISTRY

CN L-Proline, N-(carboxymethyl)-N-[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]-1-oxohexyl]glycyl-L-prolyl-L-valyl-L-valyl-L-alanyl-L-.alpha.-glutamyl-L-seryl-L-prolyl-L-lysyl-L-lysyl-, (1.fwdarw.1')-amide with L-prolyl-L-valyl-L-valyl-L-alanyl-L-.alpha.-glutamyl-L-seryl-L-prolyl-L-lysyl-L-lysyl-L-proline (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 34: PN: WO0018791 PAGE: 80 claimed sequence

CN LPA-II

NTE multichain

modified (modifications unspecified)

type	-----	location	-----	description
bridge		Gly-1	- Pro-1'	covalent bridge

SQL 21,11,10

RN 262859-57-4 REGISTRY

SEQ 1 GPVVAESPKK P

=====

HITS AT: 2-11

SEQ 1 PVVAESPKKP  
=====

HITS AT: 1-10

REFERENCE 1: 133:265384

REFERENCE 2: 132:250004

L6 ANSWER 7 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN 262859-56-3 REGISTRY

CN L-Proline, N-(carboxymethyl)-N-[(9H-fluoren-9-ylmethoxy)carbonyl]glycyl-L-prolyl-L-valyl-L-valyl-L-alanyl-L-.alpha.-glutamyl-L-seryl-L-prolyl-L-lysyl-L-lysyl-, (1.fwdarw.1')-amide with L-prolyl-L-valyl-L-valyl-L-alanyl-L-.alpha.-glutamyl-L-seryl-L-prolyl-L-lysyl-L-lysyl-L-proline (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 33: PN: WO0018791 PAGE: 79 claimed sequence

CN LPA-I

NTE multichain

modified (modifications unspecified)

type	location	description
bridge	Gly-1 - Pro-1'	covalent bridge

SQL 21,11,10

RN 262859-56-3 REGISTRY

SEQ 1 GPVVAESPKK P  
=====

HITS AT: 2-11

SEQ 1 PVVAESPKKP  
=====

HITS AT: 1-10

REFERENCE 1: 133:265384

REFERENCE 2: 132:250004

L6 ANSWER 8 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN 257289-49-9 REGISTRY

CN L-Proline, L-lysyl-L-threonyl-L-histidyl-L-asparaginyl-L-threonyl-L-lysyl-L-.alpha.-aspartyl-L-lysylglycyl-L-alanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-leucyl-L-valyl-L-lysyl-L-leucyl-L-alanyl-L-.alpha.-glutamyl-L-seryl-L-valyl-L-alanylglycyl-L-leucyl-L-leucyl-L-lysyl-L-valyl-L-alanyl-L-glutaminyl-L-.alpha.-glutamyl-L-threonyl-L-leucyl-L-asparaginyl-L-asparaginyl-L-seryl-L-valyl-L-lysyl-L-.alpha.-glutamyl-L-leucyl-L-threonyl-L-seryl-L-prolyl-L-valyl-L-valyl-L-alanyl-L-.alpha.-glutamyl-L-seryl-L-prolyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 95: PN: WO0005378 SEQID: 1 claimed protein

SQL 50

RN 257289-49-9 REGISTRY

SEQ 1 KTHNTKDKGA EELVKLAESV AGLLKVAQET LNNSVKELTS PVVAESPKKP  
=====

HITS AT: 41-50

REFERENCE 1: 132:150602

L6 ANSWER 9 OF 30 REGISTRY COPYRIGHT 2001 ACS  
 RN 257260-46-1 REGISTRY  
 CN Protein (Borrelia burgdorferi strain S-1-10 gene OspC 194-amino acid fragment) (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN 92: PN: WO0005378 SEQID: 2 claimed protein  
 SQL 194  
 RN 257260-46-1 REGISTRY

SEQ 151 DKGAEEVLKL AESVAGLLKV AQETLNNSVK ELTSPVVAES PKKP  
 =====

HITS AT: 185-194

REFERENCE 1: 132:150602

L6 ANSWER 10 OF 30 REGISTRY COPYRIGHT 2001 ACS  
 RN 246219-52-3 REGISTRY  
 CN L-Proline, L-cysteinyl-L-glutaminy-L-valyl-L-alanyl-L-leucyl-L-threonyl-L-asparaginy-L-seryl-L-valyl-L-lysyl-L-.alpha.-glutamyl-L-leucyl-L-threonyl-L-seryl-L-prolyl-L-valyl-L-valyl-L-alanyl-L-.alpha.-glutamyl-L-seryl-L-prolyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)  
 SQL 24  
 RN 246219-52-3 REGISTRY

SEQ 1 CQVALTNSVK ELTSPVVAES PKKP  
 =====

HITS AT: 15-24

REFERENCE 1: 131:285385

L6 ANSWER 11 OF 30 REGISTRY COPYRIGHT 2001 ACS  
 RN 246219-51-2 REGISTRY  
 CN L-Proline, N2-[[[2-[[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]ethoxy]ethoxy]acetyl]-L-glutaminy-L-valyl-L-alanyl-L-leucyl-L-threonyl-L-asparaginy-L-seryl-L-valyl-L-lysyl-L-.alpha.-glutamyl-L-leucyl-L-threonyl-L-seryl-L-prolyl-L-valyl-L-valyl-L-alanyl-L-.alpha.-glutamyl-L-seryl-L-prolyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

NTE modified

type	location	description
modification	Gln-1	undetermined modification

SQL 23  
 RN 246219-51-2 REGISTRY

SEQ 1 QVALTNSVKE LTSPVVAESP KKP  
 =====

HITS AT: 14-23

REFERENCE 1: 131:285385

L6 ANSWER 12 OF 30 REGISTRY COPYRIGHT 2001 ACS  
 RN 199437-17-7 REGISTRY  
 CN L-Proline, L-prolyl-L-valyl-L-valyl-L-alanyl-L-.alpha.-glutamyl-L-seryl-L-prolyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN 1: PN: WO0018791 SEQID: 1 claimed protein  
 SQL 10  
 RN 199437-17-7 REGISTRY

SEQ 1 PVVAESPKKP

HITS AT: 1-10

REFERENCE 1: 132:250004

REFERENCE 2: 130:181185

REFERENCE 3: 129:288851

REFERENCE 4: 128:21860

L6 ANSWER 13 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN **169539-68-8** REGISTRY

CN Protein (Borrelia garinii strain PTrob gene ospC outer surface) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank AJ236908-derived protein GI 5326934

CN Lipoprotein (Borrelia garinii strain Pscf gene ospC)

CN Outer surface protein C (Borrelia garinii strain Pscf gene ospC)

SQL 207

RN **169539-68-8** REGISTRY

SEQ 151 NAKKAILKTH GTKDKGAKEL EELFKSLESL SKAAQAALTN SVKELTNPVV

201 AESPCKP

HITS AT: 198-207

REFERENCE 1: 132:148850

REFERENCE 2: 124:1985

L6 ANSWER 14 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN **167361-02-6** REGISTRY

CN Lipoprotein (Borrelia burgdorferi strain B31 gene ospB) fusion protein with protein p41 (Borrelia burgdorferi strain B31) fusion protein with protein (Borrelia burgdorferi strain B31 gene ospC) (9CI) (CA INDEX NAME)

SQL 588

RN **167361-02-6** REGISTRY

SEQ 451 KAAKEMLANS VKELTSPVVA ESPKKPGTMA QYNQMHLN KSASQNVRTA

HITS AT: 467-476

REFERENCE 1: 123:283622

L6 ANSWER 15 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN **167360-90-9** REGISTRY

CN Protein (Borrelia burgdorferi strain B31 gene ospC) fusion protein with lipoprotein (Borrelia burgdorferi strain B31 gene ospA) fusion protein with lipoprotein (Borrelia burgdorferi strain B31 gene ospB) (9CI) (CA INDEX NAME)

SQL 466

RN **167360-90-9** REGISTRY

SEQ 201 PVVAESPCKP QQNVSSLDEK NSVSVDLPGE MKVLVSKEKN KDGKYDLIAT

HITS AT: 201-210

REFERENCE 1: 123:283622

L6 ANSWER 16 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN **167360-88-5** REGISTRY

CN Lipoprotein (Borrelia burgdorferi strain B31 gene ospA) fusion protein  
with lipoprotein (Borrelia burgdorferi strain B31 gene ospB) fusion  
protein with protein (Borrelia burgdorferi strain B31 gene ospC) (9CI)  
(CA INDEX NAME)  
SQL 466  
RN 167360-88-5 REGISTRY

SEQ 451 VKELTSPVVA ESPKKP  
=====

HITS AT: 457-466

REFERENCE 1: 123:283622

L6 ANSWER 17 OF 30 REGISTRY COPYRIGHT 2001 ACS  
RN 167360-72-7 REGISTRY  
CN Protein (Borrelia burgdorferi strain TRO gene ospC) (9CI) (CA INDEX NAME)  
SQL 207  
RN 167360-72-7 REGISTRY

SEQ 151 NAKKAILKTH GTKDKGAKEL EELFKSLESL SKAAQAALTN SVKELTNPVV  
=====

201 AESPKKP  
=====

HITS AT: 198-207

REFERENCE 1: 123:283622

L6 ANSWER 18 OF 30 REGISTRY COPYRIGHT 2001 ACS  
RN 167360-70-5 REGISTRY  
CN Protein (Borrelia burgdorferi strain PKO gene ospC) (9CI) (CA INDEX NAME)  
SQL 212  
RN 167360-70-5 REGISTRY

SEQ 201 TSPVVAESPK KP  
=====

HITS AT: 203-212

REFERENCE 1: 123:283622

L6 ANSWER 19 OF 30 REGISTRY COPYRIGHT 2001 ACS  
RN 167360-68-1 REGISTRY  
CN Protein (Borrelia burgdorferi strain K48 gene ospC) (9CI) (CA INDEX NAME)  
SQL 209  
RN 167360-68-1 REGISTRY

SEQ 151 DDHAKEAILK SNPTKDKGAK ALKDLSESVE SLAKAAQEAL ANSVKELTNP  
=====

201 VVAESPKKP  
=====

HITS AT: 200-209

REFERENCE 1: 123:283622

L6 ANSWER 20 OF 30 REGISTRY COPYRIGHT 2001 ACS  
RN 167360-66-9 REGISTRY  
CN Protein (Borrelia burgdorferi strain B31 gene ospC) (9CI) (CA INDEX NAME)  
SQL 210  
RN 167360-66-9 REGISTRY

SEQ 201 PVVAESPKKP  
=====

HITS AT: 201-210

REFERENCE 1: 123:283622

L6 ANSWER 21 OF 30 REGISTRY COPYRIGHT 2001 ACS  
 RN 161630-18-8 REGISTRY  
 CN Protein (Borrelia strain VS461 gene ospC) (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN Antigen (Borrelia strain VS461 gene ospC)  
 SQL 191  
 RN 161630-18-8 REGISTRY

SEQ 151 AKELEELFKS VESLSKAAKE ALSNSVKELT SPVVAESPKK P  
 ===== =

HITS AT: 182-191

REFERENCE 1: 122:185342

L6 ANSWER 22 OF 30 REGISTRY COPYRIGHT 2001 ACS  
 RN 161630-16-6 REGISTRY  
 CN Protein (Borrelia strain H9 gene ospC) (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN Antigen (Borrelia strain H9 gene ospC)  
 CN Protein (Borrelia afzelii strain H9 gene ospC reduced)  
 SQL 194  
 RN 161630-16-6 REGISTRY

SEQ 151 DKGAELEKL FKSVESLAKA AKESLTNSVK ELTNPVVAES PKKP  
 ===== =

HITS AT: 185-194

REFERENCE 1: 124:78452

REFERENCE 2: 122:185342

L6 ANSWER 23 OF 30 REGISTRY COPYRIGHT 2001 ACS  
 RN 161630-15-5 REGISTRY  
 CN Protein (Borrelia strain ACA1 gene ospC) (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN Antigen (Borrelia strain ACA1 gene ospC)  
 CN Protein (Borrelia afzelii strain ACA1 gene ospC reduced)  
 SQL 193  
 RN 161630-15-5 REGISTRY

SEQ 151 KGAEELGKLF KSVEGLVKAA QEALTNSVKE LTSPVVAESP KKP  
 ===== =

HITS AT: 184-193

REFERENCE 1: 124:78452

REFERENCE 2: 122:185342

L6 ANSWER 24 OF 30 REGISTRY COPYRIGHT 2001 ACS  
 RN 161630-11-1 REGISTRY  
 CN Protein (Borrelia strain 297 gene ospC) (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN Antigen (Borrelia strain 297 gene ospC)  
 CN Protein (Borrelia burgdorferi sensu stricto strain 297 gene ospC reduced)  
 SQL 192  
 RN 161630-11-1 REGISTRY

SEQ 151 GADELEKLFE SVKNLSKAAK EMLTNSVKEL TSPVVAESPK KP  
 ===== =

HITS AT: 183-192

REFERENCE 1: 124:78452

REFERENCE 2: 122:185342

L6 ANSWER 25 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN **161630-08-6** REGISTRY

CN Protein (Borrelia strain IP2 gene ospC) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Antigen (Borrelia strain IP2 gene ospC)

CN Protein (Borrelia burgdorferi sensu stricto strain IP2 gene ospC reduced)

SQL 192

RN **161630-08-6** REGISTRY

SEQ 151 GAEELGKLFE SVEVLSKAAK EMLANSVKEL TSPVVAESPK KP

===== ==

HITS AT: 183-192

REFERENCE 1: 124:78452

REFERENCE 2: 122:185342

L6 ANSWER 26 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN **148847-98-7** REGISTRY

CN Protein (Borrelia burgdorferi strain PBi clone pUC-PBi/ospCL+ gene ospC precursor reduced) (9CI) (CA INDEX NAME)

SQL 207

RN **148847-98-7** REGISTRY

SEQ 151 NAKKAILKTH GTKDKGAKEL EELFKSLESL SKAAQAALTN SVKELTNPVV

===

201 AESPKKP

=====

HITS AT: 198-207

REFERENCE 1: 119:110285

L6 ANSWER 27 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN **148847-97-6** REGISTRY

CN Protein (Borrelia burgdorferi strain ATCC 35210 clone pUC-B31/ospCL+ gene ospC precursor reduced) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank AE000792-derived protein GI 2689901

CN Outer surface protein (Borrelia burgdorferi gene ospC)

CN Outer surface protein C (ospC) (Borrelia burgdorferi strain B31 gene BBB19)

CN Protein (Borrelia burgdorferi strain ATCC 35210 gene ospC reduced)

SQL 210

RN **148847-97-6** REGISTRY

SEQ 201 PVVAESPKKP

=====

HITS AT: 201-210

REFERENCE 1: 128:85027

REFERENCE 2: 124:2205

REFERENCE 3: 123:220266

REFERENCE 4: 120:267636

REFERENCE 5: 119:110285



L6 ANSWER 28 OF 30 REGISTRY COPYRIGHT 2001 ACS  
RN **146990-47-8** REGISTRY  
CN Protein pC (Borrelia burgdorferi strain PKo gene pc reduced) (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN Antigen (Borrelia strain JS3 gene ospC)  
CN Protein (Borrelia afzelii strain JSB gene ospC reduced)  
CN Protein (Borrelia strain JS3 gene ospC)

SQL 194

RN **146990-47-8** REGISTRY

SEQ 151 DKGAKFKDL FESVEGLLKA AQVALTNSVK ELTSPVVAES PKKP  
=====

HITS AT: 185-194

REFERENCE 1: 124:78452

REFERENCE 2: 122:185342

L6 ANSWER 29 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN **146990-46-7** REGISTRY

CN Protein pC (Borrelia burgdorferi strain PKo gene pc precursor reduced)  
(9CI) (CA INDEX NAME)

## OTHER NAMES:

CN Outer surface protein (Borrelia burgdorferi gene ospC)

SQL 212

RN **146990-46-7** REGISTRY

SEQ 201 TSPVVAESPK KP  
=====

HITS AT: 203-212

REFERENCE 1: 123:220266

REFERENCE 2: 118:186033

L6 ANSWER 30 OF 30 REGISTRY COPYRIGHT 2001 ACS

RN **138756-96-4** REGISTRY

CN Protein pC (Borrelia burgdorferi clone pDS1PC5 22-kilodalton reduced)  
(9CI) (CA INDEX NAME)

SQL 212

RN **138756-96-4** REGISTRY

SEQ 201 TSPVVAESPK KP  
=====

HITS AT: 203-212

REFERENCE 1: 116:82044

=> fil hcaplus  
 FILE 'HCAPLUS' ENTERED AT 18:42:37 ON 26 JUN 2001  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 26 Jun 2001 VOL 135 ISS 1  
 FILE LAST UPDATED: 25 Jun 2001 (20010625/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=> d stat que l10  
 L10 19 SEA FILE=HCAPLUS ABB=ON PLU=ON "OSTERGAARD S"/AU OR ("OSTERGAARD SOREN"/AU OR "OSTERGAARD SOREN"/IN)

=>  
 =>

=> d ibib abs l10 1-19.

L10 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 2000:844273 HCAPLUS  
 DOCUMENT NUMBER: 134:129026  
 TITLE: Short communication: associations between blood calcium status at calving and milk yield in dairy cows  
 AUTHOR(S): **Ostergaard, S.**; Larsen, T.  
 CORPORATE SOURCE: Dep. Anim. Health Welfare, Res. Cent. Foulum, Dan. Inst. Agric. Sci., Tjele, DK-8830, Den.  
 SOURCE: J. Dairy Sci. (2000), 83(11), 2438-2440  
 CODEN: JDSCAE; ISSN: 0022-0302  
 PUBLISHER: American Dairy Science Association  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The purpose of the present study was to est. the effect of total blood plasma calcium (TBPCC) concn. at calving on milk yield in dairy cows. Data originated from 153 dairy cows in 27 herds from a single veterinary practice. For each cow, data included calcium concn. in a blood sample taken within 12 h postpartum, monthly test-day milk yield until 300 days in milk, calving date, parity, breed, and herd. The TBPCC ranged from 0.69 to 2.73 mmol/L, with a mean value of 1.80 mmol/L. The statistical anal. adjusted for the fixed effects of parity and lactation stage, random effects of herd and cow, and the correlation between repeated measures of test-day milk yield. TBPCC at calving was not significantly related to fat- and protein-cor. milk yield at any lactation period. Hypocalcemia

(low TBPPC) at calving is not an important risk factor for decreased milk yield.

REFERENCE COUNT: 15  
 REFERENCE(S): (4) Gitelman, H; Anal Biochem 1967, V18, P521 HCAPLUS  
 (5) Horst, R; J Dairy Sci 1997, V80, P1269 HCAPLUS  
 (11) Ostergaard, S; J Dairy Sci 1999, V82, P1188 HCAPLUS  
 (12) Ostergaard, S; J Dairy Sci 2000, V83, P721 HCAPLUS  
 (14) Rajala-Schultz, P; J Dairy Sci 1999, V82, P288 HCAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 2000:569091 HCAPLUS  
 DOCUMENT NUMBER: 133:265384  
 TITLE: Ligand-presenting assembly: a method for C- and N-terminal antigen presentation  
 AUTHOR(S): Holm, A.; Jorgensen, R. M.; **Ostergaard, S.**; Theisen, M.  
 CORPORATE SOURCE: Research Center for Medical Biotechnology, Chemistry Department, The Royal Veterinary and Agricultural University, Copenhagen, DK-1871, Den.  
 SOURCE: J. Pept. Res. (2000), 56(2), 105-113  
 CODEN: JPERFA; ISSN: 1397-002X  
 PUBLISHER: Munksgaard International Publishers Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Achiral dicarboxylic acids were coupled with 2 equiv. of the free .alpha.-amino groups of two fully side-chain protected peptide chains while these were still attached to a synthesis resin. Cleavage from the resin with simultaneous side-chain deprotection afforded two assembled peptide chains with free C-terminals. Suitable functionalization of the achiral dicarboxylic acid alternatively permitted continued peptide synthesis in a C to N orientation leading to a final peptide assembly which, after cleavage from the resin, may have multiple N to C and C to N presentation of one or more epitopes.

REFERENCE COUNT: 16  
 REFERENCE(S): (1) Aletras, A; J Peptide Protein Res 1995, V45, P488 HCAPLUS  
 (2) Bhatnagar, P; J Med Chem 1996, V39, P3814 HCAPLUS  
 (3) Brandt, L; J Immunol 1996, V157, P3527 HCAPLUS  
 (5) Keah, H; J Peptide Res 1998, V51, P2 HCAPLUS  
 (6) Kim, H; J Med Chem 1994, V37, P3373 HCAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 2000:291651 HCAPLUS  
 TITLE: A stochastic model simulating the feeding-health-production complex in a dairy herd  
 AUTHOR(S): **Ostergaard, S.**; Sorensen, J. T.; Kristensen, A. R.  
 CORPORATE SOURCE: Department of Animal Science and Animal Health, Royal Veterinary and Agricultural University, Copenhagen, DK-1870, Den.  
 SOURCE: J. Dairy Sci. (2000), 83(4), 721-733  
 CODEN: JDSCAE; ISSN: 0022-0302  
 PUBLISHER: American Dairy Science Association  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB A dynamic, stochastic, and mechanistic Monte Carlo model, simulating a dairy herd with focus on the feeding-health-prodn. complex is presented. By specifying biol. parameters at cow level and a management strategy at

herd level, the model can simulate the tech. and economic consequences of scenarios at herd level. The representation of the feeding-health-prodn. complex is aimed to be sufficiently detailed, to include relationships likely to cause significant herd effects, and to be sufficiently simple to enable a feasible parameterization of the model and interpretation of the results from the model. Consequently, diseases are defined as four disease types: two metabolic disease types, an udder disease type, and a reproductive disease type. Risk factors for the diseases were defined as parity, yield capacity, disease recurrence, disease interrelationships, lactation stage, and season. Direct effects of the diseases were defined according to milk yield, feed intake, feed utilization, conception, culling, involuntary removal, and death. Scenarios differing in base risks of milk fever and ketosis, heat detection rate, and culling strategy were simulated for describing the model behavior. Annual milk yield per cow was decreased by increased risk of ketosis and by increased risk of milk fever, even though no direct effect of milk fever on milk yield was modeled at the cow level. The indirect effect from milk fever is a consequence of increased replacement rate (relatively lower milk yield from younger cows). By ignoring the history of milk fever in insemination and replacement decisions, a significantly reduced net income per cow was found in some herds. We concluded that important benefits from using such a herd model are the capability of accounting for herd management factors and the advantage of avoiding to double count the indirect effects from disease, such as increased risk of other diseases, poorer reprodn. results, and increased risk of culling and death.

REFERENCE COUNT: 43  
 REFERENCE(S): (4) Detilleux, J; J Dairy Sci 1994, V77, P3316 HCAPLUS  
 (18) Grohn, Y; J Dairy Sci 1995, V78, P1693 HCAPLUS  
 (19) Grohn, Y; J Dairy Sci 1998, V81, P966 HCAPLUS  
 (22) Heuer, C; J Dairy Sci 1999, V82, P295 HCAPLUS  
 (31) Ostergaard, S; J Dairy Sci 1999, V82, P1188 HCAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 2000:288716 HCAPLUS  
 DOCUMENT NUMBER: 133:135599  
 TITLE: Complex and diverse motif bead libraries based on the peptomer (peptide/peptoid hybrid polymer) approach  
 AUTHOR(S): **Ostergaard, Soren**; Hansen, Per Hertz  
 CORPORATE SOURCE: Novo Nordisk A/S, Bagsvaerd, 2880, Den.  
 SOURCE: Pept. 1998, Proc. Eur. Pept. Symp., 25th (1999), Meeting Date 1998, 758-759. Editor(s): Bajusz, Sandor; Hudecz, Ferenç. Akademiai Kiado: Budapest, Hung.  
 CODEN: 68WKAY  
 DOCUMENT TYPE: Conference  
 LANGUAGE: English  
 AB A symposium report. TentaGel resin-bound peptide libraries (contg. peptide/peptoid hybrid polymers) were synthesized and screened against streptavidin alk. phosphatase under low and high stringency conditions.  
 REFERENCE COUNT: 3  
 REFERENCE(S): (1) stergaard, S; J Peptide Sci 1997, V3, P123  
 (2) stergaard, S; Mol Div 1997, V3, P17  
 (3) Zuckermann, R; J Am Chem Soc 1992, V114, P10646 HCAPLUS

L10 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 2000:227686 HCAPLUS  
 DOCUMENT NUMBER: 132:284221  
 TITLE: NCAM-binding compounds for stimulation of nerve outgrowth and proliferation of NCAM-presenting cells  
 INVENTOR(S): Ronn, Lars Christian B.; Bock, Elisabeth; Holm, Arne;

PATENT ASSIGNEE(S): Olsen, Marianne; **Ostergaard, Soren**; Jensen,  
 SOURCE: Peter H.; Poulsen, Flemming M.; Soroka, Vladislav;  
 Ralets, Igor; Berezin, Vladimir  
 Den.  
 PCT Int. Appl., 119 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000018801	A2	20000406	WO 1999-DK500	19990923
WO 2000018801	A3	20000713		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9957274	A1	20000417	AU 1999-57274	19990923
PRIORITY APPLN. INFO.:			DK 1998-1232	A 19980929
			DK 1999-592	A 19990429
			WO 1999-DK500	W 19990923

OTHER SOURCE(S): MARPAT 132:284221

AB The invention provides novel compds. which are able to stimulate proliferation or/and outgrowth from cells presenting the neural cell adhesion mol. (NCAM). Addnl., the invention relates to pharmaceutical compns., medicaments and methods for treatment of normal, degenerated and damaged NCAM-presenting cells.

L10 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:227676 HCAPLUS  
 DOCUMENT NUMBER: 132:250004  
 TITLE: Ligand presenting assembly (LPA), method of preparation and uses thereof  
 INVENTOR(S): Holm, Arne; Jorgensen, Rikke Malene; **Ostergaard, Soren**; Theisen, Michael  
 PATENT ASSIGNEE(S): Statens Serum Institut, Den.  
 SOURCE: PCT Int. Appl., 100 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000018791	A1	20000406	WO 1999-DK510	19990929
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9960783	A1	20000417	AU 1999-60783	19990929

PRIORITY APPLN. INFO.: DK 1998-1233 A 19980929  
WO 1999-DK510 W 19990929

OTHER SOURCE(S): MARPAT 132:250004

AB The present invention relates to a method for prepg. a Ligand Presenting Assembly (LPA), an LPA, an immunol. compn. and a vaccine. The N-terminal of LPA is coupled to an achiral di, tri, or tetra-carboxylic acid so as to provide a construct having a ring structure. The invention further relates to a method for generating antibodies, a kit for use in diagnosis and use of an LPA for prepg. a pharmaceutical compn.

REFERENCE COUNT: 7

REFERENCE(S): (1) Anthony, G; WO 9402506 A 1994 HCAPLUS  
(2) Golding Louise; WO 9832469 A 1998 HCAPLUS  
(3) Harboe, M; INFECTION AND IMMUNITY 1998, V66(2), P717 HCAPLUS  
(4) Peluso, S; TETRAHEDRON 1997, V53(21), P7231 HCAPLUS  
(5) Statens Seruminstitut; WO 9742221 A 1997 HCAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:34958 HCAPLUS

DOCUMENT NUMBER: 132:88169

TITLE: Peptide antagonists of the human urokinase plasminogen activator receptor, selection method, and therapeutic use, especially for the treatment of cancer

INVENTOR(S): Ploug, Michael; **Ostergaard, Soren**; Holm, Arne; Holst-Hansen, Claus; Stephens, Ross W.; Dano, Keld

PATENT ASSIGNEE(S): Cancerforskningsfonden Af 1989 (Fonden Til Fremme Af Eksperimentel Cancerforskning, Den.

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000001802	A2	20000113	WO 1999-DK377	19990701
WO 2000001802	A3	20000427		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9947688	A1	20000124	AU 1999-47688	19990701

PRIORITY APPLN. INFO.: DK 1998-874 A 19980701  
WO 1999-DK377 W 19990701

AB A set of inhibitors of the binding interaction between human urokinase plasminogen activator (uPA) and its cell surface receptor (uPAR) has been developed. The inhibitors comprise peptide fragments, monomeric or in multiple copies attached to a common scaffold, in which the amino acid sequence may include uncommon substituted amino acids to partially comprise of peptoid sequences. The invention also relates to the use of such peptides in therapy, in particular for the treatment of cancer, having developed a modified non-human mammalian receptor to which the novel inhibitors are antagonistic.

L10 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:683626 HCAPLUS  
DOCUMENT NUMBER: 131:349587  
TITLE: Identification of a neuritogenic ligand of the neural cell adhesion molecule using a combinatorial library of synthetic peptides  
AUTHOR(S): Ronn, Lars C. B.; Olsen, Marianne; **Ostergaard, Soren**; Kiselyov, Vladislav; Berezin, Vladimir; Mortensen, Marie T.; Lerche, Mathilde H.; Jensen, Peter H.; Soroka, Vladislav; Saffells, Jane L.; Doherty, Patrick; Poulsen, Flemming M.; Bock, Elisabeth; Holm, Arne  
CORPORATE SOURCE: Protein Lab., Inst. Mol. Pathol., Panum Inst. 6.2, Univ. Copenhagen, Copenhagen N, DK-2200, Den.  
SOURCE: Nat. Biotechnol. (1999), 17(10), 1000-1005  
CODEN: NABIF9; ISSN: 1087-0156  
PUBLISHER: Nature America  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB The neural cell adhesion mol. (NCAM) plays a key role in neural development, regeneration, and learning. In this study, we identified a synthetic peptide-ligand of the NCAM Ig1 module by combinatorial chem. and showed it could modulate NCAM-mediated cell adhesion and signal transduction with high potency. In cultures of dissociated neurons, this peptide, termed C3, stimulated neurite outgrowth by activating a signaling pathway identical to that activated by homophilic NCAM binding. A similar effect was shown for the NCAM Ig2 module, the endogenous ligand of NCAM Ig1. By NMR spectroscopy, the C3 binding site in the NCAM Ig1 module was mapped and shown to be different from the binding site of the NCAM Ig2 module. The C3 peptide may prove useful as a lead in development of therapies for neurodegenerative disorders, and the C3 binding site of NCAM Ig1 may represent a target for discovery of nonpeptide drugs.  
REFERENCE COUNT: 41  
REFERENCE(S): (1) Beggs, H; J Biol Chem 1997, V272, P8310 HCAPLUS  
(2) Bothner-By, A; J Am Chem Soc 1984, V106, P811 HCAPLUS  
(4) Covault, J; Proc Natl Acad Sci USA 1985, V82, P4544 HCAPLUS  
(5) Cremer, H; Nature 1994, V367, P455 HCAPLUS  
(6) Cwirla, S; Science 1997, V276, P1696 HCAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:399862 HCAPLUS  
TITLE: Effects of diseases on test day milk yield and body weight of dairy cows from Danish research herds  
AUTHOR(S): **Ostergaard, S.**; Grohn, Y. T.  
CORPORATE SOURCE: Department of Animal Science and Animal Health, Royal Veterinary and Agricultural University, Copenhagen, DK-1870, Den.  
SOURCE: J. Dairy Sci. (1999), 82(6), 1188-1201  
CODEN: JDSCAE; ISSN: 0022-0302  
PUBLISHER: American Dairy Science Association  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB The pre- and postdisease interrelationships of energy cor. test day milk yield and body wt. of dairy cows caused by mastitis, three reproductive disorders (retained placenta, metritis, cystic ovaries), and seven metabolic disorders (milk fever, ketosis, decreased rumen motility, enteritis, left displaced abomasum, right displaced abomasum, and off feed) were quantified by using mixed models anal. with repeated measures of continuous data. The data were weekly recordings from 4414 lactations collected in three Danish research herds. High milk yield was a risk

factor for ketosis and enteritis. Heavier primiparous cows were more likely to contract mastitis. Milk yield was decreased for a disease-specific period for all study diseases except cystic ovaries and right displaced abomasum. Metabolic disorders had a detrimental effect on body wt. The highest wt. loss (69 kg) was assocd. with left displaced abomasum. The persistence of the wt. loss differed considerably among study diseases. Almost all wt. loss occurred up to and including the initial week after diagnosis, which emphasized the detrimental effect of the subclin. stage. However, weekly measured body wt. seemed superior to weekly energy cor. test day milk yield for disease detection only for decreased rumen motility and left displaced abomasum. This study demonstrates the importance of the predisease level for accurate estn. of the loss of milk yield and body wt. from disease.

REFERENCE COUNT: 39

REFERENCE(S): (4) Coulon, J; J Dairy Sci 1996, V79, P44 HCAPLUS  
(6) Detilleux, J; J Dairy Sci 1994, V77, P3316 HCAPLUS  
(7) Detilleux, J; J Dairy Sci 1997, V80, P121 HCAPLUS  
(17) Grohn, Y; J Dairy Sci 1995, V78, P1693 HCAPLUS  
(26) Lescourret, F; J Dairy Sci 1995, V78, P2167  
HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:38999 HCAPLUS

DOCUMENT NUMBER: 130:179184

TITLE: Identification and purification of O-acetyl-L-serine  
sulphydrylase in *Penicillium chrysogenum*

AUTHOR(S): **Ostergaard, S.**; Theilgaard, H. B. Aa.;  
Nielsen, J.

CORPORATE SOURCE: Centre for Process Biotechnology, Department of  
Biotechnology, Technical University of Denmark,  
Lyngby, DK-2800, Den.

SOURCE: Appl. Microbiol. Biotechnol. (1998), 50(6), 663-668  
CODEN: AMBIDG; ISSN: 0175-7598

PUBLISHER: Springer-Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The authors demonstrate that *P. chrysogenum* possesses the L-cysteine biosynthetic enzyme O-acetyl-L-serine sulphydrylase (EC 4.2.99.8) (I) of the direct sulphydrylation pathway. The finding of I, and thus the presence of the direct sulphydrylation pathway in *P. chrysogenum*, creates the potential for increasing the overall yield in penicillin prodn. by enhancing the enzymic activity of this microorganism. Only I and O-acetyl-L-homoserine sulphydrylase (EC 4.2.99.10) (II) have been demonstrated to use O-acetyl-L-serine as substrate for the formation of L-cysteine. Purified I did not catalyze the formation of L-homocysteine from O-acetyl-L-homoserine and sulfide, thus excluding the possibility that the purified enzyme was a II with multiple substrate specificity. I purifn. enhanced the specific activity 93-fold in relation to the cell-free ext. Two bands, showing exactly the same intensity, were present in SDS-PAGE, and the mol. wts. of these were estd. to be 59 and 68 kDa, resp. The Km and Vmax values of I with O-acetyl-L-serine as substrate were estd. as 1.3 mM and 14.9 .mu.mol/mg protein/h, resp. Purified I had a temp. optimum of .apprx.45.degree., which was much higher than the actual temp. for penicillin synthesis. Furthermore, I exhibited max. activity in the range of pH 7.0-7.4.

REFERENCE COUNT: 19

REFERENCE(S): (1) Becker, M; J Biol Chem 1969, V244, P2418 HCAPLUS  
(2) Bradford, M; Anal Biochem 1976, V72, P248 HCAPLUS  
(3) Brzywczy, J; Acta Biochim Pol 1993, V40, P421  
HCAPLUS  
(4) Christensen, L; J Biotechnol 1995, V42, P95  
HCAPLUS



(5) Coque, J; Eur J Biochem 1996, V242, P264 HCAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:574780 HCAPLUS  
DOCUMENT NUMBER: 129:288851  
TITLE: The dominant epitope of *Borrelia garinii* outer surface protein C recognized by sera from patients with neuroborreliosis has a surface-exposed conserved structural motif  
AUTHOR(S): Mathiesen, Marianne J.; Holm, Arne; Christiansen, Michael; Blom, Jens; Hansen, Klaus; **Ostergaard, Soren**; Theisen, Michael  
CORPORATE SOURCE: Department of Clinical Biochemistry, Statens Serum Institut, Copenhagen, DK-2300, Den.  
SOURCE: Infect. Immun. (1998), 66(9), 4073-4079  
CODEN: INFIBR; ISSN: 0019-9567  
PUBLISHER: American Society for Microbiology  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Epitope mapping of outer surface protein C (OspC) by using sera from patients with neuroborreliosis led to the identification of one single major immunodominant epitope within the C-terminal 10 amino acid residues. Peptide binding studies and alanine replacement scanning of the C-terminal decapeptide, PVVAESPKKP, revealed a crit. role for the PKKP sequence and its terminal carboxyl group for the binding of IgM (IgM) antibodies from patients with Lyme borreliosis. Electron microscopy of antibody-labeled spirochetes indicated that the C-terminal region is exposed on the surface of the spirochete. Based on homol. to proteins of known function, this region most probably adopts a polyproline II-like helix, which is found in surface-exposed structures involved in protein-protein interactions. This structural motif is highly conserved in *Borrelia* species causing Lyme borreliosis and subjected to purifying selection. We suggest that the abundance of the C-terminal region of OspC on the surface of *B. burgdorferi* allows a multimeric high-avidity interaction between the spirochete and surface Igs on B cells. The resulting crosslinking of surface Igs on B cells may induce a T-cell-independent B-cell activation without IgM-to-IgG switching, thus explaining the lack of IgG antibodies to OspC in neuroborreliosis.

L10 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:206221 HCAPLUS  
DOCUMENT NUMBER: 129:3180  
TITLE: Evidence against protein kinase B as a mediator of contraction-induced glucose transport and GLUT4 translocation in rat skeletal muscle  
AUTHOR(S): Lund, S.; Pryor, P. R.; **Ostergaard, S.**; Schmitz, O.; Pedersen, O.; Holman, G. D.  
CORPORATE SOURCE: Kommunehospital, Aarhus Kommunehospital and Medical Department M (Endocrinology and Diabetes), Medical Research Laboratory, Aarhus University Hospital, Aarhus, 8000, Den.  
SOURCE: FEBS Lett. (1998), 425(3), 472-474  
CODEN: FEBLAL; ISSN: 0014-5793  
PUBLISHER: Elsevier Science B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Both insulin and muscle contraction stimulate glucose transport activity. However, contraction stimulation does not involve the insulin signaling intermediate phosphatidylinositol 3-kinase (PI 3-kinase). Protein kinase B (PKB) has recently been identified as a direct downstream target of PI 3-kinase in the insulin signaling pathway. We have examd. here whether the 2 stimuli share PKB as a convergent step in sep. signaling pathways.

Insulin stimulates both glucose transport, GLUT4 cell-surface content, and PKB activity (by 4-6-fold above basal) in a wortmannin-sensitive manner in vitro incubated rat soleus muscles. By contrast, muscle contraction, which stimulates glucose transport and the cell surface content of GLUT4 by 3-fold above basal levels, had no effect on PKB activity. These data demonstrate that PKB is not a mediator of contraction-induced glucose transport and GLUT4 translocation.

L10 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:138306 HCAPLUS  
DOCUMENT NUMBER: 128:230665  
TITLE: Peptomers: a versatile approach for the preparation of diverse combinatorial peptidomimetic bead libraries  
AUTHOR(S): **Ostergaard, Soren**; Holm, Arne  
CORPORATE SOURCE: Novo Research Institute, Bagsvaerd, DK-2880, Den.  
SOURCE: Mol. Diversity (1997), 3(1), 17-27  
CODEN: MODIF4; ISSN: 1381-1991  
PUBLISHER: Kluwer Academic Publishers  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB This report describes a versatile approach in the generation of peptidomimetic bead libraries. The method is based on the prepn. of peptide-peptoid hybrids using the portioning-mixing procedure, which gives diverse peptidomimetic bead libraries composed of peptides, peptoids and peptide-peptoid hybrids. We term these peptomers, from peptide-peptoid hybrid polymers. The synthesis of the peptomers is easily accomplished by adapting the peptoid synthesis strategy, in which a primary amine reacts with bromoacetic acid, and we combine this methodol. with conventional peptide synthesis. The sequence of the active compd. is deduced by conventional microsequencing using Edman degrdn. chem., thus avoiding the synthesis of a coding structure or the addn. of mol. tags. We demonstrate the utility of the peptomer approach by the synthesis of a bead library together with the identification of novel peptidomimetic ligands binding to the macromol. targets streptavidin and the insulin receptor.

L10 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:129640 HCAPLUS  
DOCUMENT NUMBER: 128:267353  
TITLE: Photoaffinity Labeling of the Human Receptor for Urokinase-Type Plasminogen Activator Using a Decapeptide Antagonist. Evidence for a Composite Ligand-Binding Site and a Short Interdomain Separation  
AUTHOR(S): Ploug, Michael; **Ostergaard, Soren**; Hansen, Lars Bo Laurenborg; Holm, Arne; Dano, Keld  
CORPORATE SOURCE: Finsen Laboratory, Rigshospitalet, Copenhagen, DK-2100, Den.  
SOURCE: Biochemistry (1998), 37(11), 3612-3622  
CODEN: BICHAW; ISSN: 0006-2960  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Binding of urokinase-type plasminogen activator (uPA) to its cellular receptor (uPAR) renders the cell surface a favored site for plasminogen activation. Recently, a 15-mer peptide antagonist of the uPA-uPAR interaction, with an IC50 value of 10 nM, was identified using phage display technol. [Goodson, R. J., Doyle, M. V., Kaufman, S. E., and Rosenberg, S. (1994) Proc. Natl. Acad. Sci. 91, 7129-7133]. In the present study, the mol. aspects of the interaction between this peptide and uPAR have been investigated. We have characterized the real-time receptor binding kinetics for the antagonist using surface plasmon resonance and identified crit. residues by alanine replacements. The minimal peptide antagonist thus derived (SLNFSQYLWS) was rendered photoactivatable by replacing residues important for uPAR binding with

WO 1997-DK203 19970502

AB A diagnostic method is disclosed which utilizes short C-terminal fragments of *Borrelia burgdorferi* sensu lato derived protein OspC. A 4 N-terminal amino acid peptide (Pro-Lys-Lys-Pro) is shown to be essential in immune reactivity between sera from patients suffering from early borreliosis and various OspC derivs. and it is shown that to be effective as a diagnostic agent, 5 consecutive amino acid residues must be present. Therefore, an immunol. agent used according to the invention comprises a .gtoreq. 5 amino acid residues long homolog of a fragment identical to the 10 C-terminal amino acids of OspC. Also disclosed are vaccines utilizing the short peptides as well as methods for their prepn.

L10 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:336552 HCAPLUS  
 DOCUMENT NUMBER: 127:62746  
 TITLE: Characterization of *Chlamydia trachomatis* L2-induced tyrosine-phosphorylated HeLa cell proteins by two-dimensional gel electrophoresis  
 AUTHOR(S): Birkelund, Svend; Bini, Luca; Pallini, Vitaliano; Sanchez-Campillo, Maria; Liberatori, Sabrina; Clausen, Johannes D.; **Ostergaard, Soren**; Holm, Arne; Christiansen, Gunna  
 CORPORATE SOURCE: Department Medical Microbiology Immunology, University Aarhus, Aarhus, DK-8000, Den.  
 SOURCE: Electrophoresis (1997), 18(3-4), 563-567  
 CODEN: ELCTDN; ISSN: 0173-0835  
 PUBLISHER: VCH  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB *Chlamydia trachomatis* is an obligate intracellular bacterium, inducing its own uptake in nonprofessional phagocytes either by phagocytosis or pinocytosis. We have previously shown that *C. trachomatis* L2 induces tyrosine phosphorylation of eukaryotic proteins upon their entry by phagocytosis. In this paper we characterize the tyrosine-phosphorylated proteins by two-dimensional gel electrophoresis. In immunoblotting with anti-phosphotyrosine antibodies of *C. trachomatis* L2-infected HeLa cells, but not with uninfected cells, two rows of spots were obsd. with a mol. mass of 69 and 71 kDa and pI from 5.0 to 5.2. In addn., a single spot of 100 kDa and pI 6.2 was obsd.

L10 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1996:98222 HCAPLUS  
 DOCUMENT NUMBER: 124:139108  
 TITLE: The 18-kilodalton *Chlamydia trachomatis* histone H1-like protein (Hcl) contains a potential N-terminal dimerization site and a C-terminal nucleic acid-binding domain  
 AUTHOR(S): Pedersen, Lotte Bang; Birkelund, Svend; Holm, Arne; **Ostergaard, Soren**; Christiansen, Gunna  
 CORPORATE SOURCE: Department Medical Microbiology, University Aarhus, DK-8000, Den.  
 SOURCE: J. Bacteriol. (1996), 178(4), 994-1002  
 CODEN: JOBAAY; ISSN: 0021-9193  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The *Chlamydia trachomatis* histone H1-like protein (Hcl) is a DNA-binding protein specific for the metabolically inactive chlamydial developmental form, the elementary body. Hcl induces DNA condensation in *Escherichia coli* and is a strong inhibitor of transcription and translation. These effects may, in part, be due to Hcl-mediated alterations of DNA topol. To locate putative functional domains within Hcl, polypeptides Hcl2-57 and Hcl53-125, corresponding to the N- and C-terminal parts of Hcl, resp., were generated. By chem. crosslinking with ethylene glycol-bis(succinic

acid N-hydroxysuccinimide ester), purified recombinant Hcl was found to form dimers. The dimerization site was located in the N-terminal part of Hcl (Hcl12-57). Moreover, CD measurements indicated an overall .alpha.-helical structure of this region. By using limited proteolysis, Southwestern blotting, and gel retardation assays, Hcl153-225 was shown to contain a domain capable of binding both DNA and RNA. Under the same conditions, Hcl12-57 had no nucleic acid-binding activity. Electron microscopy of Hcl-DNA and Hcl153-125-DNA complexes revealed differences suggesting that the N-terminal part of Hcl may affect the DNA-binding properties of Hcl.

L10 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:508605 HCAPLUS.

DOCUMENT NUMBER: 123:105758

TITLE: Novel avidin and streptavidin binding sequences found in synthetic peptide libraries

AUTHOR(S): **Ostergaard, Soren**; Hansen, Per Hertz; Olsen, Marianne; Holm, Arne

CORPORATE SOURCE: Research Center for Medical Biotechnology, Chemistry Department Royal Veterinary and Agricultural University, Thorvaldsensvej 40, Copenhagen, DK-1871, Den.

SOURCE: FEBS Lett. (1995), 362(3), 306-8

CODEN: FEBLAL; ISSN: 0014-5793

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Synthetic resin-bound peptide libraries made of protein L-amino acids were synthesized. During screening of the libraries, peptides that bind to avidin were identified contg. a novel motif with 2 histidines sepd. by 1 residue. A sublibrary was synthesized and screened, and new crit. residues appeared surrounding the 2 histidines. Addnl. peptide libraries made of L-amino acids were screened with avidin and streptavidin and novel motifs found.

=>

=> d stat que l12

L9 10 SEA FILE=HCAPLUS ABB=ON PLU=ON "JORGENSEN R"/AU OR "JORGENSEN R M"/AU OR "JORGENSEN RIKKE MALENE"/AU OR "JORGENSEN RIKKE MALENE"/IN

L10 19 SEA FILE=HCAPLUS ABB=ON PLU=ON "OSTERGAARD S"/AU OR ("OSTERGAARD SOREN"/AU OR "OSTERGAARD SOREN"/IN)

L12 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 NOT L10

=>

=>

=> d ibib abs l12 1-8

L12 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:776352 HCAPLUS

DOCUMENT NUMBER: 134:66270

TITLE: Creation of a selective antagonist and agonist of the rat VPAC1 receptor using a combinatorial approach with vasoactive intestinal peptide 6-23 as template

AUTHOR(S): Tams, Jeppe Wegener; **Jorgensen, Rikke Malene**; Holm, Arne; Fahrenkrug, Jan

CORPORATE SOURCE: Department of Clinical Biochemistry, Bispebjerg Hospital, Copenhagen, Den.

SOURCE: Mol. Pharmacol. (2000), 58(5), 1035-1041

CODEN: MOPMA3; ISSN: 0026-895X

PUBLISHER: American Society for Pharmacology and Experimental

Therapeutics  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB We have used combinatorial chem. with amino acid mixts. (X) at positions 6 to 23 in vasoactive intestinal peptide (VIP) to optimize binding affinity and selectivity to the rat VPAC1 receptor. The most efficient amino acid replacement was a substitution of alanine at position 18 to diphenylalanine (Dip), increasing the displacement efficiency of 125I-VIP by 370-fold. The [Dip18]VIP(6-23) was subsequently used to find a second replacement, employing the same approach. Tyrosine at position 9 was selected and the resulting [Tyr9,Dip18]VIP(6-23) analog has a  $K_i$  value of 90 nM. This analog was unable to stimulate cAMP prodn. at  $10^{-6}$  M but was able to inhibit VIP-induced cAMP stimulation ( $K_b = 79$  nM). The  $K_i$  values of [Tyr9,Dip18]VIP(6-23) using the rat VPAC2 and PAC1 receptors were 3000 nM and >10,000 nM, resp. Thus, [Tyr9,Dip18]VIP(6-23) is a selective VPAC1 receptor antagonist. The C-terminally extended form, [Tyr9,Dip18]VIP(6-28), displays improved antagonistic properties having a  $K_i$  and  $K_b$  values of 18 nM and 16 nM, resp. On the contrary, the fully extended form, [Tyr9,Dip18]VIP(1-28), was a potent agonist with improved binding affinity ( $K_i = 0.11$  nM) and ability to stimulate cAMP ( $EC_{50} = 0.23$  nM) compared with VIP ( $K_i = 1.7$  nM,  $EC_{50} = 1.12$  nM). Furthermore, the specificity of this agonist to the VPAC1 receptor was high, the  $K_i$  values for the VPAC2 and PAC1 receptors were 53 nM and 3, 100 nM, resp. Seven other analogs with the [Tyr9,Dip18] replacement combined with previously published VIP modifications have been synthesized and described in this work.

REFERENCE COUNT: 27  
REFERENCE(S): (1) Arimura, A; Jpn J Physiol 1998, V48, P301 HCAPLUS  
(3) Cheng, Y; Biochem Pharmacol 1973, V22, P3099 HCAPLUS  
(4) Dickinson, T; Neuropeptides 1997, V31, P175 HCAPLUS  
(5) Fahrenkrug, J; Pharmacol Toxicol 1993, V72, P354 HCAPLUS  
(7) Gaddum, J; Pharmacol Rev 1957, V9, P211 HCAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:352774 HCAPLUS  
DOCUMENT NUMBER: 134:126665  
TITLE: Assignment of the human mitochondrial translational release factor 1 (MTRF1) to chromosome 13q14.1.fwdarw.q14.3 and of the human mitochondrial ribosome recycling factor (MRRF) to chromosome 9q32.fwdarw.q34.1 with radiation hybrid mapping  
AUTHOR(S): Hansen, L. L.; Jorgensen, R.; Justesen, J.  
CORPORATE SOURCE: Institute of Human Genetics, Aarhus University, Aarhus, DK-8000, Den.  
SOURCE: Cytogenet. Cell Genet. (2000), 88(1-2), 91-92  
CODEN: CGCGBR; ISSN: 0301-0171  
PUBLISHER: S. Karger AG  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The ribosome recycling factor MRRF is a nuclear encoded mitochondrial protein, which is necessary for recycling of ribosomes after the termination of a peptide chain catalyzed by the mitochondrial translation release factor 1 (MTRF1). MRRF- and MTRF1-specific PCR primers and the Genebridge radiation hybrid panel were used to map the MRRF gene to human chromosome 9q32.fwdarw.q34.1 and the MTRF1 gene to chromosome 13q14.1.fwdarw.q14.3.

REFERENCE COUNT: 1  
REFERENCE(S): (1) Zhang, Y; Biochim biophys Acta 1998, V1443, P245 HCAPLUS

L12 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:423354 HCAPLUS  
 DOCUMENT NUMBER: 131:119904  
 TITLE: Methodology for hydrocarbon speciation for heavy duty diesel engines operating over the European ECE R49 cycle  
 AUTHOR(S): Reynolds, E. G.; Hall, D. E.; Jorgensen, R.; Kvinge, F.  
 CORPORATE SOURCE: BP Oil, USA  
 SOURCE: Soc. Automot. Eng., [Spec. Publ.] SP (1999), SP-1459(Topics in General Emissions), 95-99  
 CODEN: SAESA2; ISSN: 0099-5908  
 PUBLISHER: Society of Automotive Engineers  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB A methodol. has been developed to enable a single, gaseous sample to be collected from the dild. exhaust stream of heavy duty diesel engines operating over the European 13 mode ECE R49 emission cycle. The sample consists of timed contributions of dil. exhaust gas from each mode (weighted appropriately) to provide a gas sample that is representative of the complete cycle. The sample is collected in a Tedlar bag prior to GC anal. for individual hydrocarbon speciation. This methodol. has also been extended to allow for the collection of a representative carbonyl sample using 2,4-dinitrophenylhydrazine (2,4-DNPH) impregnated cartridges. Results obtained from these systems are reported and compared to results obtained from light duty (diesel and gasoline) investigations.

REFERENCE COUNT: 7

REFERENCE(S): (1) AQIRP (US Auto/Oil Quality Improvement Research Programme; SAE SP-1000 and SAE SP-920 1993  
 (2) Bennett, P; SAE961901  
 (3) European Commission; European Programme on Emissions Fuels and Engine Technology EPEFE 1996  
 (4) International Agency for Research on Cancer; IARC Group 1 1987  
 (5) International Agency for Research on Cancer; IARC Group 2A 1998

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1992:252182 HCAPLUS  
 DOCUMENT NUMBER: 116:252182  
 TITLE: Conditional male fertility in chalcone synthase-deficient petunia  
 AUTHOR(S): Taylor, L. P.; Jorgensen, R.  
 CORPORATE SOURCE: Dep. Hortic. Landscape Archit., Washington State Univ., Pullman, WA, 99164-6414, USA  
 SOURCE: J. Hered. (1992), 83(1), 11-17  
 CODEN: JOHEA8; ISSN: 0022-1503  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Transgenic petunia plants with suppressed chalcone synthase gene expression produce abnormal anthers devoid of flavonoid pigments. Although viable pollen is produced, pollen germination, and tube growth are severely reduced both in vivo and in vitro. This results in plants that are self-sterile. Pollen from the transgenic plants is partially rescued by inbred V26 stigmas, resulting in seed set that is approx. 30% of normal. Female fertility in the transgenic petunia is unaffected by the lack of flavonoids. The term conditional male fertility (CMF) is proposed to describe the state in which viable but flavonoid-deficient pollen does not function in self-crosses and is partially functional on wild-type stigmas. Although this condition has attributes of both male sterility and self-incompatibility, it is clearly different. This observation in petunia has similarities to the earlier report of Coe et

al. (1981) that most pollinations made with chalcone synthase (CHS)-deficient maize pollen were unsuccessful. The possibility that normal development of the male gametophyte requires flavonoid synthesis in many or all higher plants is discussed. The dominant CHS deficiency and male sterility in petunia, taken together with the recessive CHS deficiency and male sterility in maize, suggest that flavonoid synthesis in the sporophyte rather than the gametophyte is required for fertility.

L12 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1978:185977 HCAPLUS  
 DOCUMENT NUMBER: 88:185977  
 TITLE: Transposable neomycin phosphotransferases  
 AUTHOR(S): Davies, Julian; Berg, D.; **Jorgensen, R.**;  
 Fianndt, M.; Huang, T. S. R.; Courvalin, P.; Schloff, J.  
 CORPORATE SOURCE: Dep. Biochem., Univ. Wisconsin, Madison, Wis., USA  
 SOURCE: Top. Infect. Dis. (1977), 2(R-Factors: Their Prop. Possible control), 101-14  
 CODEN: TIDID3  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Of the transposons which contain genes for resistance to aminoglycoside antibiotics, 3 encode aminoglycoside 3'-phosphotransferase: Tn6, Tn601, and Tn5. The Tn6 insertion in the .lambda. phage genome is unstable, whereas Tn5 and Tn601 are much more stable. Tn5 is transposed from .lambda. to the Escherichia coli chromosome, and from 1 chromosomal site to another, at high frequency. A phys. map for Tn5 insertions in the lacZ gene of E. coli is presented.

L12 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1978:166548 HCAPLUS  
 DOCUMENT NUMBER: 88:166548  
 TITLE: Genetic organization in the transposable tetracycline resistance determinant Tn10  
 AUTHOR(S): **Jorgensen, R.**; Berg, D.; Reznikoff, W.  
 CORPORATE SOURCE: Coll. Agric. Life Sci., Univ. Wisconsin, Madison, Wis., USA  
 SOURCE: Microbiology (Washington, D. C.) (1978) 181-3  
 CODEN: MICRDG; ISSN: 0098-1540  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Restriction endonuclease fragments of phage .lambda. bearing the 9400-base-pair tetracycline (I)-resistance transposon Tn10 were inserted into plasmid pVH51, and Escherichia coli recipients were transformed with the resulting plasmids. Plasmid DNA from 8 I-resistant clones was isolated and mapped with restriction endonucleases. All 8 plasmids had a common 2025-base-pair fragment which must represent the genes for I-resistance. The min. inhibitory concn. of I for the hosts varied, so sequences outside fragment 2025 must also play a role in regulating resistance.

L12 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1974:476611 HCAPLUS  
 DOCUMENT NUMBER: 81:76611  
 TITLE: Changes in milk, whey, and blue cheese as induced by benzoyl peroxide  
 AUTHOR(S): Washam, C. J.; Reinbold, G. W.; Vedamuthu, E. R.; **Jorgensen, R.**  
 CORPORATE SOURCE: Iowa State Univ., Ames, Iowa, USA  
 SOURCE: J. Milk Food Technol. (1974), 37(2), 244-9  
 CODEN: JMFTAT  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Heating of whey proteins (60.degree. for 2 hr) in the presence of benzoyl peroxide had a pronounced effect on the proteins, but polyacrylamide gel electrophoresis revealed changes in proteins not attributable to heat alone. Benzoyl peroxide-heat treated cheeses tended to expel moisture during leakage tests. During blue cheese manuf., benzoyl peroxide at 17.8 ppm whitened the cheese more than at 5.9 ppm, and this was true even when heat treatment was omitted. Use of benzoyl peroxide in the bleaching process did not decrease mold development in ripening loaves nor was acid prodn. by lactic cultures diminished. In addn., proteolysis of milk proteins by rennet was not reduced by benzoyl peroxide.

L12 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1967:405343 HCAPLUS  
 DOCUMENT NUMBER: 67:5343  
 TITLE: Nonmagnetic interconnect material for welded modules  
 AUTHOR(S): **Jorgensen, R. M.**  
 CORPORATE SOURCE: California Inst. of Technol., Pasadena, Calif., USA  
 SOURCE: NASA (Nat. Aeronaut. Space Admin.) Access. (1965),  
 NASA-CR-64605, 90-3 Avail.: CFSTI, \$3 cy  
 From: Sci. Tech. Aerospace Rept. 1965, 3(21),  
 N65-32430  
 CODEN: NAACAF  
 DOCUMENT TYPE: Report  
 LANGUAGE: English

AB While many materials are nonmagnetic, very few approach Ni in terms of its utility as an interconnect material for welded cordwood. The unique characteristics of Ni that lend themselves to a welding interconnect are discussed and the classes of materials which may be investigated in order to find a nonmagnetic material to replace Ni are considered. An exptl. approach to detg. the feasibility of materials is based upon choosing the same conductor cross section that has been found to be optimum for Ni and comparing the results obtained to the weldability of Ni. The optimum Ni conductor cross section is 0.010 by 0.030 in.<sup>2</sup> and this size is compatible with 0.017 to 0.040-in. diam. gold-plated Kovar; 0.016 to 0.030-in. diam. Dumet; 0.016 to 0.032-inch diam. Ni; 0.016 to 0.032-in. diam. O-free Cu; and 0.020 to 0.032-in. diam. ETP Cu wires when cross-wire welded. It is noted that Ni is close to being an ideal material in regard to ductility and freedom from weld-zone embrittlement. Therefore equaling the weldability of Ni may not be easy.

=>  
=>

=> d stat que l14

L7 63 SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLM A"/AU OR "HOLM A"/IN)  
 L8 146 SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLM ARNE"/AU OR "HOLM  
 ARNE"/IN)  
 L9 10 SEA FILE=HCAPLUS ABB=ON PLU=ON "JORGENSEN R"/AU OR "JORGENSEN  
 R M"/AU OR "JORGENSEN RIKKE MALENE"/AU OR "JORGENSEN RIKKE  
 MALENE"/IN  
 L10 19 SEA FILE=HCAPLUS ABB=ON PLU=ON "OSTERGAARD S"/AU OR ("OSTERGA  
 ARD SOREN"/AU OR "OSTERGAARD SOREN"/IN)  
 L11 45 SEA FILE=HCAPLUS ABB=ON PLU=ON ("THEISEN M"/AU OR "THEISEN  
 M"/IN OR "THEISEN M J"/AU OR "THEISEN M O"/AU) OR ("THEISEN  
 MICHAEL"/AU OR "THEISEN MICHAEL"/IN OR "THEISEN MICHAEL J"/AU)  
 L12 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 NOT L10  
 L13 41 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 NOT (L10 OR L12)  
 L14 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L7 OR L8)

=>  
=>



=&gt; d ibib abs 114 1

L14 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:787484 HCAPLUS

DOCUMENT NUMBER: 130:181185

TITLE: Peptide-based OspC enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis

AUTHOR(S): Mathiesen, Marianne J.; Christiansen, Michael; Hansen, Klaus; Holm, Arne; Asbrink, Eva; Theisen, Michael

CORPORATE SOURCE: Department of Clinical Biochemistry, Statens Serum Institut, Copenhagen, DK-2300, Den.

SOURCE: J. Clin. Microbiol. (1998), 36(12), 3474-3479

CODEN: JCMIDW; ISSN: 0095-1137

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Sera from 210 patients with Lyme borreliosis (LB) were studied by an ELISA based on a synthetic peptide (pepC10) comprising the C-terminal 10-amino-acid residues of OspC of *Borrelia burgdorferi*. The authors found that 36.3 and 45.0% of the serum samples from patients with erythema migrans (EM) and neuroborreliosis (NB), resp., displayed IgM anti-pepC10 reactivities, while these samples rarely (.ltoreq.8%) displayed IgG antibody reactivities. Sera from patients with acrodermatitis chronica atrophicans did not contain anti-pepC10 antibodies. The diagnostic performance of this newly developed peptide ELISA was compared with those of an ELISA based on the full-length recombinant OspC protein (rOspC) and a com. available ELISA based on the *B. burgdorferi* flagellum (Fla). The sensitivity of the IgM pepC10 ELISA was slightly lower than that of the rOspC ELISA for EM patients (36.3 vs. 43.8%), while there was no difference for NB patients (45.0 vs. 48.0%). However, the optical d. values obtained by the pepC10 ELISA were generally higher than those obtained by the rOspC ELISA, leading to a significantly better quant. discrimination between seropos. patients with NB and controls. The specificity of the pepC10 ELISA was similar to those of the rOspC ELISA and the Fla ELISA for relevant controls including patients with syphilis and mononucleosis. Although the overall diagnostic sensitivity of the Fla ELISA was superior, 8.8 and 12.0% of the EM and NB patients, resp., were antibody pos. only by the pepC10 ELISA. Thus, use of a diagnostic test for LB based on the detection of IgM antibodies to pepC10 and Fla has increased sensitivity for the diagnosis of early LB.

REFERENCE COUNT: 43

REFERENCE(S): (3) Altschul, S; J Mol Biol 1990, V215, P403 HCAPLUS  
 (4) Amouriaux, P; Res Microbiol 1993, V144, P211 HCAPLUS  
 (6) Bresters, D; J Med Virol 1992, V37, P187 HCAPLUS  
 (7) Bruckbauer, H; Eur J Clin Microbiol Infect Dis 1992, V11, P224 HCAPLUS  
 (8) Dressler, F; J Infect Dis 1994, V169, P313 HCAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; d stat que 115

L7 63 SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLM A"/AU OR "HOLM A"/IN)  
 L8 146 SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLM ARNE"/AU OR "HOLM ARNE"/IN)  
 L9 10 SEA FILE=HCAPLUS ABB=ON PLU=ON "JORGENSEN R"/AU OR "JORGENSEN R M"/AU OR "JORGENSEN RIKKE MALENE"/AU OR "JORGENSEN RIKKE MALENE"/IN  
 L10 19 SEA FILE=HCAPLUS ABB=ON PLU=ON "OSTERGAARD S"/AU OR ("OSTERGAARD SOREN"/AU OR "OSTERGAARD SOREN"/IN)  
 L11 45 SEA FILE=HCAPLUS ABB=ON PLU=ON ("THEISEN M"/AU OR "THEISEN

```

M"/IN OR "THEISEN M J"/AU OR "THEISEN M O"/AU) OR ("THEISEN
MICHAEL"/AU OR "THEISEN MICHAEL"/IN OR "THEISEN MICHAEL J"/AU)
L12      8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 NOT L10
L13     41 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11 NOT (L10 OR L12)
L14      1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L13 AND (L7 OR L8)
L15     19 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L13 AND (ANTIGEN? OR
ASSEMBL? OR LPA? OR LIGAND? OR (AMINO(W)ACID? OR AA OR PEPTIDE
OR PROTEIN)(W)SYSTEM?)) NOT L14

```

=>  
=>

=> d ibib abs htirn l15 1-19  
'HTIRN' IS NOT A VALID FORMAT FOR FILE 'HCAPLUS'  
ENTER DISPLAY FORMAT (BIB):end

=> d ibib abs 1-19

```

L15 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:829948 HCAPLUS
DOCUMENT NUMBER: 134:112771
TITLE: Conservation and heterogeneity of the glutamate-rich
protein (GLURP) among field isolates and laboratory
lines of Plasmodium falciparum
AUTHOR(S): Stricker, K. D.; Vuust, J.; Jepsen, S.; Oeuvray, C.;
Theisen, M.
CORPORATE SOURCE: Department of Clinical Biochemistry, Statens Serum
Institut, Copenhagen, DK-2300, Den.
SOURCE: Mol. Biochem. Parasitol. (2000), 111(1), 123-130
CODEN: MBIPDP; ISSN: 0166-6851
PUBLISHER: Elsevier Science Ireland Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Genetic variation of the glutamate-rich protein (GLURP) of Plasmodium
falciparum was analyzed in 29 field isolates and 15 lab. lines of diverse
geog. origin, by DNA sequencing of the non-repetitive 5'-region (R0) of
the glurp gene. Polymorphism with respect to the length of the GLURP R2
repeat region was also analyzed by a polymerase chain reaction method. As
ref., the nucleotide sequence of the highly polymorphic 3'-region of the
circumsporozoite protein gene was detd. in the same isolates. It was
found that even in the presence of variations in the GLURP R2 repeat
region, immunodominant parts of the GLURP R0 region are surprisingly well
conserved and the conservation is most pronounced in isolates from
locations with very high malaria transmission. This might indicate that
the R0 structure plays an important role in the parasite.
REFERENCE COUNT: 30
REFERENCE(S): (4) Bouharoun-Tayoun, H; J Exp Med 1995, V182, P409
HCAPLUS
(5) Doodoo, D; J Infect Dis 2000, V181, P1202 HCAPLUS
(6) Doolan, D; Infect Immun 1992, V60, P675 HCAPLUS
(7) Dziegiel, M; Infect Immun 1993, V61, P103 HCAPLUS
(9) Escalante, A; Genetics 1998, V149, P189 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```

```

L15 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:526193 HCAPLUS
DOCUMENT NUMBER: 134:264768
TITLE: Identification of a major B-cell epitope of the
Plasmodium falciparum glutamate-rich protein (GLURP),
targeted by human antibodies mediating parasite
killing
AUTHOR(S): Theisen, M.; Soe, S.; Jessing, S. G.;

```

Okkels, L. M.; Danielsen, S.; Oeuvray, C.; Druilhe, P.; Jepsen, S.  
 CORPORATE SOURCE: Dep. Clinical Biochem., Statens Serum Inst., Copenhagen, Den.  
 SOURCE: Vaccine (2000), 19(2-3), 204-212  
 CODEN: VACCDE; ISSN: 0264-410X  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The **antigenicity** of the glutamate-rich protein (GLURP) of *Plasmodium falciparum* was comprehensively evaluated in epitope-mapping studies utilizing a phage display library, synthetic peptides and anti-GLURP IgG preps. previously shown to promote strong antibody-dependent cellular inhibition (ADCI) effects. We identified six major B-cell epitopes within the nonrepetitive region R0, corresponding to amino acid residues 173 to 187 (P1), 193 to 207 (P3), 216 to 229 (P4), 264 to 288 (P11), 343 to 357 (P10), and 407 to 434 (S3). Of these, four (P1, P3, P4, and S3) were frequently recognized by high-titered IgG antibodies in plasma samples from immune Liberian adults (prevalence: 29.1-45.0%). The three epitopes P1, P3, and P4 contained a common motif (seven out of nine positions are identical) and may thus constitute a family of structurally related epitopes. This leaves two distinct epitopes, one (P3) representing this new epitope family and S3 as targets for biol. active antibodies. Human IgG antibodies from single plasma samples were affinity-purified against these peptides. P3-specific IgG preps. were consistently more effective in ADCI than S3-specific IgG. Among the different GLURP epitopes, we therefore suggest that the P3 epitope is potentially the most important epitope in GLURP for the development of clin. immunity to malaria in man.

REFERENCE COUNT: 28  
 REFERENCE(S): (5) Bouharoun-Tayoun, H; J Exp Med 1995, V182, P409 HCAPLUS  
 (9) Druilhe, P; Immunol Lett 1994, V41, P115 HCAPLUS  
 (11) Dziejgiel, M; Infect Immun 1993, V61, P103 HCAPLUS  
 (14) Jacobsson, K; Biotechniques 1996, V20, P1070 HCAPLUS  
 (15) Khusmith, S; Infect Immun 1983, V41, P219 HCAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:358998 HCAPLUS  
 DOCUMENT NUMBER: 133:118838  
 TITLE: **Antigenic** equivalence of human T-cell responses to *Mycobacterium tuberculosis*-specific RD1-encoded protein **antigens** ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides  
 AUTHOR(S): Arend, Sandra M.; Geluk, Annemieke; Van Meijgaarden, Krista E.; Van Dissel, Jaap T.; **Theisen, Michael**; Andersen, Peter; Ottenhoff, Tom H. M.  
 CORPORATE SOURCE: Department of Infectious Diseases, Leiden University Medical Center, Leiden, 2300, Neth.  
 SOURCE: Infect. Immun. (2000), 68(6), 3314-3321  
 CODEN: INFIBR; ISSN: 0019-9567  
 PUBLISHER: American Society for Microbiology  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The early secreted **antigenic** target 6-kDa protein (ESAT-6) and culture filtrate protein 10 (CFP-10) are promising **antigens** for reliable immunodiagnosis of tuberculosis. Both **antigens** are encoded by RD1, a genomic region present in all strains of *Mycobacterium tuberculosis* and *M. bovis* but lacking in all *M. bovis* bacillus Calmette-Guerin vaccine strains. Prodn. and purifn. of recombinant

**antigens** are laborious and costly, precluding rapid and large-scale testing. Aiming to develop alternative diagnostic reagents, we have investigated whether recombinant ESAT-6 (rESAT-6) and recombinant CFP-10 (rCFP-10) can be replaced with corresponding mixts. of overlapping peptides spanning the complete amino acid sequence of each **antigen**. Proliferation of *M. tuberculosis*-specific human T-cell lines in response to rESAT-6 and rCFP-10 and that in response to the corresponding peptide mixts. were almost completely correlated ( $r = 0.96$ ,  $P < 0.0001$  for ESAT-6;  $r = 0.98$ ,  $P < 0.0001$  for CFP-10). More importantly, the same was found when gamma interferon prodn. by peripheral blood mononuclear cells in response to these stimuli was analyzed ( $r = 0.89$ ,  $P < 0.0001$  for ESAT-6;  $r = 0.89$ ,  $P < 0.0001$  for CFP-10). Whole protein **antigens** and the peptide mixts. resulted in identical sensitivity and specificity for detection of infection with *M. tuberculosis*. The peptides in each mixt. contributing to the overall response varied between individuals with different HLA-DR types. Interestingly, responses to CFP-10 were significantly higher in the presence of HLA-DR15, which is the major subtype of DR2. These results show that mixts. of synthetic overlapping peptides have potency equiv. to that of whole ESAT-6 and CFP-10 for sensitive and specific detection of infection with *M. tuberculosis*, and peptides have the advantage of faster prodn. at lower cost.

REFERENCE COUNT: 30  
 REFERENCE(S): (1) Andersen, P; Infect Immun 1991, V59, P1905 HCAPLUS  
 (6) Behr, M; Science 1999, V284, P1520 HCAPLUS  
 (7) Berthet, F; Microbiology 1998, V144, P3195 HCAPLUS  
 (9) Brosch, R; Infect Immun 1998, V66, P2221 HCAPLUS  
 (10) Cole, S; Nature 1998, V393, P537 HCAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:287414 HCAPLUS  
 DOCUMENT NUMBER: 133:295081  
 TITLE: Naturally acquired antibodies to the glutamate-rich protein are associated with protection against *Plasmodium falciparum* malaria  
 AUTHOR(S): Dodoo, Daniel; Theisen, Michael; Kurtzhals, Jorgen A. L.; Akanmori, Bartholomew D.; Koram, Kwadwo A.; Jepsen, Soren; Nkrumah, Francis K.; Theander, Thor G.; Hviid, Lars  
 CORPORATE SOURCE: Immunology and Epidemiology Units, University of Ghana, Legon, Ghana  
 SOURCE: J. Infect. Dis. (2000), 181(3), 1202-1205  
 CODEN: JIDIAQ; ISSN: 0022-1899  
 PUBLISHER: University of Chicago Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The development of effective malaria vaccines depends on the identification of targets of well-defined protective immune responses. Data and samples from a longitudinal study of a cohort of children from coastal Ghana were used to investigate the role of antibody responses to 3 regions of the *Plasmodium falciparum* glutamate-rich protein (GLURP). These data show that levels of the GLURP-specific IgG that occurs in the nonrepeat region of the **antigen** are significantly correlated with clin. protection from *P. falciparum* malaria, after correction for the confounding effect of age. Furthermore, levels of cytophilic antibodies were found to be of particular importance for protection, lending support to the hypothesis that antibody-dependent cellular inhibition is the important element in GLURP-specific protective immunity.

REFERENCE COUNT: 14  
 REFERENCE(S): (3) Bouharoun-Tayoun, H; Infect Immun 1992, V60, P1473 HCAPLUS  
 (5) Dodoo, D; Infect Immun 1999, V67, P2131 HCAPLUS  
 (6) Dziegiel, M; Am J Trop Med Hyg 1991, V44, P306

## HCAPLUS

(7) Dziegiel, M; Infect Immun 1993, V61, P103 HCAPLUS  
 (9) Khusmith, S; Infect Immun 1983, V41, P219 HCAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:282549 HCAPLUS

DOCUMENT NUMBER: 133:41887

TITLE: Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal  
 AUTHOR(S): Qeuvray, Claude; **Theisen, Michael**; Rogier, Christophe; Trape, Jean-Francois; Jepsen, Soren; Druilhe, Pierre

CORPORATE SOURCE: Laboratoire de Parasitologie BioMedicale, Institut Pasteur, Paris, 75015, Fr.

SOURCE: Infect. Immun. (2000), 68(5), 2617-2620

CODEN: INFIBR; ISSN: 0019-9567

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The goal of this study was to analyze antibody responses to Plasmodium falciparum glutamate-rich protein (GLURP) using clin. data and plasma samples obtained from villagers of Dielmo, Senegal. This mol. was chosen because it is targeted by human antibodies which induce parasite growth inhibition in antibody-dependent cellular inhibition (ADCI) assays. The results showed a strong correlation between protection against malaria attacks and levels of IgG2 and IgG3 against GLURP94-489 (R0) and IgG3 against GLURP705-1178 (R2) when cor. for the confounding effect of age-related exposure to malaria. Thus, GLURP may play a role in the induction of protective immunity against P. falciparum malaria.

REFERENCE COUNT: 23

REFERENCE(S): (4) Bouharoun-Tayoun, H; Infect Immun 1992, V60, P1473 HCAPLUS

(6) Bouharoun-Tayoun, H; J Exp Med 1995, V182, P409 HCAPLUS

(8) Dziegiel, M; Infect Immun 1993, V61, P103 HCAPLUS

(9) Foreback, J; Inflammation 1997, V21, P501 HCAPLUS

(16) Sarthou, J; Infect Immun 1997, V65, P3271 HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:155853 HCAPLUS

DOCUMENT NUMBER: 132:304796

TITLE: Triple helix **assembly** and processing of human collagen produced in transgenic tobacco plants  
 AUTHOR(S): Ruggiero, F.; Exposito, J.-Y.; Bournat, P.; Gruber, V.; Perret, S.; Comte, J.; Olagnier, B.; Garrone, R.; **Theisen, M.**

CORPORATE SOURCE: Institut de Biologie et Chimie des Proteines, CNRS UPR 412, Universite Lyon I, Lyon, F-69367, Fr.

SOURCE: FEBS Lett. (2000), 469(1), 132-136

CODEN: FEBLAL; ISSN: 0014-5793

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The use of tobacco plants as a novel expression system for the prodn. of human homotrimeric collagen I is presented in this report. Constructs were engineered from cDNA encoding the human pro.alpha.1(I) chain to generate transgenic tobacco plants expressing collagen I. The recombinant pro.alpha.1(I) chains were expressed as disulfide-bonded trimers and were shown to fold into a stable homotrimeric triple helix. Moreover, the recombinant procollagen was subsequently processed to collagen as it

occurs in animals. Large amts. of recombinant collagen were purified from field grown plant material. The data suggest that plants are a valuable alternative for the recombinant prodn. of collagen for various medical and scientific purposes.

REFERENCE COUNT: 27

REFERENCE(S): (1) Berg, R; Biochem Biophys Res Commun 1973, V52, P115 HCAPLUS  
(2) Bulleid, N; Biochem J 1996, V317, P195 HCAPLUS  
(3) Cornelissen, B; Nature 1986, V321, P531 HCAPLUS  
(4) Denecke, J; Plant Cell 1995, V7, P391 HCAPLUS  
(6) Elefteriou, F; J Biol Chem 1997, V272, P22866 HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:765518 HCAPLUS

DOCUMENT NUMBER: 132:75375

TITLE: Crystal structure of SQD1, an enzyme involved in the biosynthesis of the plant sulfolipid headgroup donor UDP-sulfoquinovose

AUTHOR(S): Mulichak, Anne M.; **Theisen, Michael J.**;  
Essigmann, Bernd; Benning, Christoph; Garavito, R. Michael

CORPORATE SOURCE: Department of Biochemistry, Michigan State University, East Lansing, MI, 48824-1319, USA

SOURCE: Proc. Natl. Acad. Sci. U. S. A. (1999), 96(23), 13097-13102

CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The SQD1 enzyme is believed to be involved in the biosynthesis of the sulfoquinovosyl headgroup of plant sulfolipids, catalyzing the transfer of SO<sub>3</sub><sup>-</sup> to UDP-glucose. We have detd. the structure of the complex of SQD1 from Arabidopsis thaliana with NAD<sup>+</sup> and the putative substrate UDP-glucose at 1.6-Å. resoln. Both bound **ligands** are completely buried within the binding cleft, along with an internal solvent cavity which is the likely binding site for the, as yet, unidentified sulfur-donor substrate. SQD1 is a member of the short-chain dehydrogenase/reductase (SDR) family of enzymes, and its structure shows a conservation of the SDR catalytic residues. Among several highly conserved catalytic residues, Thr-145 forms unusually short hydrogen bonds with both susceptible hydroxyls of UDP-glucose. A His side chain may also be catalytically important in the sulfonation.

REFERENCE COUNT: 48

REFERENCE(S): (1) Baker, M; FEBS Lett 1992, V301, P89 HCAPLUS  
(2) Benning, C; Annu Rev Plant Physiol Plant Mol Biol 1998, V49, P53 HCAPLUS  
(3) Benning, C; J Bacteriol 1992, V174, P2352 HCAPLUS  
(4) Benning, C; J Bacteriol 1992, V174, P6479 HCAPLUS  
(5) Benning, C; Proc Natl Acad Sci USA 1993, V90, P1561 HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:750692 HCAPLUS

DOCUMENT NUMBER: 132:235685

TITLE: IgG reactivities against recombinant rhoptry-associated protein-1 (rRAP-1) are associated with mixed Plasmodium infections and protection against disease in Tanzanian children

AUTHOR(S): Alifrangis, M.; Lemnge, M. M.; Moon, R.; **Theisen, M.**; Bygbjerg, I.; Ridley, R. G.; Jakobsen, P. H.

CORPORATE SOURCE: Centre for Medical Parasitology, Institute of Medical Microbiology and Immunology, Panum Institute, University of Copenhagen, Copenhagen, 2200, Den.

SOURCE: Parasitology (1999), 119(4), 337-342  
CODEN: PARAAE; ISSN: 0031-1820

PUBLISHER: Cambridge University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A cross-sectional sero-epidemiol. study was performed in Magoda, Tanzania, an area where malaria is holoendemic. Blood samples were collected from children (1-4 yr) and tested for IgG antibody reactivity against 2 recombinant protein fragments of Plasmodium falciparum Rhoptry-Assocd. Protein-1 (rRAP-1). The data were related to the prevalence of malarial disease and single P. falciparum or mixed Plasmodium infections. Fever ( $t_{0.05} = 37.5^{\circ}\text{C}$ ) in combination with parasite densities  $>5000/\mu\text{l}$  were used to distinguish between children with asymptomatic malaria infections and those with acute clin. disease. Furthermore, C-reactive protein (CRP) was applied as a surrogate marker of malaria morbidity. The prevalence of Plasmodium infections was 96.0%. Eleven children were defined as clin. malaria cases, all with single P. falciparum infections. The d. of P. falciparum was significantly lower in children with mixed Plasmodium infections compared to those with single P. falciparum infections. Children with asymptomatic P. falciparum infections had higher IgG reactivities to rRAP-1, compared to IgG reactivities of children with malarial disease. Children with mixed Plasmodium infections generally showed elevated IgG reactivity to rRAP-1, when compared to children with single P. falciparum infections. The possible relationship between mixed species infections, clin. outcome of the disease and antibody responses to RAP-1 is discussed.

REFERENCE COUNT: 18

REFERENCE(S): (3) Beck, H; Journal of Infectious Diseases 1997, V175, P921 HCAPLUS  
(5) Fonjongo, P; Infection and Immunity 1998, V66, P1037 HCAPLUS  
(6) Howard, R; Molecular and Biochemical Parasitology 1996, V77, P95 HCAPLUS  
(8) Jakobsen, P; American Journal of Tropical Medicine and Hygiene 1996, V55, P642 HCAPLUS  
(9) Jakobsen, P; Immunology Letters 1997, V59, P35 HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:363176 HCAPLUS

DOCUMENT NUMBER: 129:121333

TITLE: Identification and characterization of a 29-kilodalton protein from Mycobacterium tuberculosis culture filtrate recognized by mouse memory effector cells

AUTHOR(S): Rosenkrands, Ida; Rasmussen, Peter Birk; Carnio, Markus; Jacobsen, Susanne; **Theisen, Michael**; Andersen, Peter

CORPORATE SOURCE: Department of TB Immunology, Statens Serum Institut, Copenhagen S, DK-2300, Den.

SOURCE: Infect. Immun. (1998), 66(6), 2728-2735  
CODEN: INFIBR; ISSN: 0019-9567

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Culture filtrate proteins from Mycobacterium tuberculosis induce protective immunity in various animal models of tuberculosis. Two mol. mass regions (6 to 10 kDa and 24 to 36 kDa) of short-term culture filtrate are preferentially recognized by Th1 cells in animal models as well as by patients with minimal disease. In the present study, the 24- to 36-kDa

region has been studied, and the T-cell reactivity has been mapped in detail. Monoclonal antibodies were generated, and one monoclonal antibody, HYB 71-2, with reactivity against a 29-kDa **antigen** located in the highly reactive region below the **antigen** 85 complex was selected. The 29-kDa **antigen** (CFP29) was purified from *M. tuberculosis* short-term culture filtrate by thiophilic adsorption chromatog., anion-exchange chromatog., and gel filtration. In its native form, CFP29 forms a polymer with a high mol. mass. CFP29 was mapped in two-dimensional electrophoresis gels as three distinct spots just below the **antigen** 85 complex component MPT59. CFP29 is present in both culture filtrate and the membrane fraction from *M. tuberculosis*, suggesting that this **antigen** is released from the envelope to culture filtrate during growth. Detn. of the N-terminal amino acid sequence allowed cloning and sequencing of the *cfp29* gene. The nucleotide sequence showed 62% identity to the bacteriocin Linocin from *Brevibacterium linens*. Purified recombinant histidine-tagged CFP29 and native CFP29 had similar T-cell stimulatory properties, and they both elicited the release of high levels of gamma interferon from mouse memory effector cells isolated during the recall of protective immunity to tuberculosis. Interspecies anal. by immunoblotting and PCR demonstrated that CFP29 is widely distributed in mycobacterial species.

L15 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:117548 HCAPLUS  
 DOCUMENT NUMBER: 128:216349  
 TITLE: Inflammatory reactions in placental blood of *Plasmodium falciparum*-infected women and high concentrations of soluble E-selectin and a circulating *P. falciparum* protein in the cord sera  
 AUTHOR(S): Jakobsen, P. H.; Rasheed, F. N.; Bulmer, J. N.; **Theisen, M.**; Ridley, R. G.; Greenwood, B. M.  
 CORPORATE SOURCE: Departments of Clinical Microbiology, Copenhagen University Hospital, Den.  
 SOURCE: Immunology (1998), 93(2), 264-269  
 CODEN: IMMUAM; ISSN: 0019-2805  
 PUBLISHER: Blackwell Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB To better understand reasons for increased susceptibility to malaria in pregnancy and the interrelationships between maternal malaria, local immune reactions and the development of the fetus, concns. of sol. interleukin-10 (IL-10), cytokine receptors, adhesion mols., a *Plasmodium falciparum* protein, glutamate-rich protein (GLURP) and antibodies to *P. falciparum* rhoptry-assocd. protein-1 were measured among 105 Gambian women and their neonates. Peripheral blood concns. of IL-10, sol. cytokine receptors and sol. adhesion mols. were found to be different from those concns. measured in the placenta. Markers of inflammatory reactions: IL-10, sIL-2R, sIL-4R, and sol. tumor necrosis factor receptor I (sTNF-RI) were found in high concns. in the placenta, indicating that inflammatory reactions take place in the placenta which has been regarded as an immunoprivileged site. Concns. of sol. vascular cell adhesion mol.-1 (sVCAM-1) and sol. intracellular adhesion mol.-1 (sICAM-1), potential adhesion receptors for malaria parasites, were assocd. with an active *P. falciparum* infection in the placenta although the assocns. did not reach significance. *P. falciparum* exoantigen, GLURP, was detected in cord blood indicating transplacental passage of malarial **antigens**. Concns. of E-selectin were higher in cord blood samples compared with peripheral blood samples. This appeared to be assocd. with development of cord endothelial cells and not with *P. falciparum* infection.

L15 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:7799 HCAPLUS  
 DOCUMENT NUMBER: 128:113917



TITLE: The glutamate-rich protein (GLURP) of *Plasmodium falciparum* is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro

AUTHOR(S): **Theisen, Michael**; Soe, Soe; Oeuvray, Claude; Thomas, Alan W.; Vuust, Jens; Danielsen, Steffen; Jepsen, Soren; Druilhe, Pierre

CORPORATE SOURCE: Department of Clinical Biochemistry, Statens Seruminstitut, Copenhagen, DK-2300, Den.

SOURCE: Infect. Immun. (1998), 66(1), 11-17  
CODEN: INFIBR; ISSN: 0019-9567

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Monocyte-dependent as well as direct inhibitory effects of antimalarial antibodies point toward **antigens** accessible at the time of merozoite release as targets for biol. active antibodies capable of mediating protection against *Plasmodium falciparum*. The glutamate-rich protein (GLURP), being an **antigen** assocd. with mature schizont-infected erythrocytes, was therefore the object of the present investigation, in which the authors analyzed whether anti-GLURP antibodies can either interfere directly with merozoite invasion or act indirectly by promoting a monocyte-dependent growth inhibition, antibody-dependent cellular inhibition. GLURP-specific human IgG antibodies, from pooled IgG of healthy Liberian adults who were clin. immune to malaria, were purified by affinity chromatog. on columns contg. R0 (N-terminal non-repetitive region of GLURP) or R2 (C-terminal repetitive region of GLURP) recombinant protein or synthetic peptides as **ligands**. Anal. of the pattern of reactivity of highly purified anti-GLURP antibodies led to the definition of at least four B-cell epitopes. One epitope was specific for R0, two were specific for R2, and the fourth displayed cross-reactivity between R0 and R2. None of the purified IgG antibodies had direct invasion-inhibitory effects, even at high concns. In contrast, when allowed to cooperate with monocytes, all anti-GLURP IgG preps. mediated a strong monocyte-dependent parasite growth inhibition in a dose-dependent manner.

L15 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:87580 HCAPLUS

DOCUMENT NUMBER: 126:143233

TITLE: Analysis of the human antibody response to outer surface protein C (OspC) of *Borrelia burgdorferi sensu stricto*, *B. garinii*, and *B. afzelii*

AUTHOR(S): Mathiesen, Marianne Jartved; Hansen, Klaus; Axelsen, Nils; Halkier-Soerensen, Lars; **Theisen, Michael**

CORPORATE SOURCE: Borrelia Laboratory, Department of Clinical Biochemistry, Copenhagen, DK-2300, Den.

SOURCE: Med. Microbiol. Immunol. (1996), 185(3), 121-129  
CODEN: MMIYAO; ISSN: 0300-8584

PUBLISHER: Springer

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The aim of this study was to det. by Western blotting (WB) the prevalence of anti-outer surface protein C (OspC) IgM and IgG antibodies in patients with Lyme borreliosis according to each of the three genospecies of *Borrelia burgdorferi sensu lato*. Strains of *B. burgdorferi sensu stricto* (MUL), *B. garinii* (DK 6), and *B. afzelii* (DK 26) served as **antigen**, all of which expressed abundant OspC. The authors examd. sera from 117 patients with untreated early and late Lyme borreliosis, as well as from 100 blood donors and 29 patients with syphilis. WB results were compared with the *B. burgdorferi* flagellum ELISA (ELISA) data. OspC from *B. burgdorferi sensu stricto* showed the lowest diagnostic sensitivity. OspC

from *B. garinii* and *B. afzelii* performed almost identically in erythema migrans, with an IgM pos. rate of 36 vs. 34%, whereas OspC from *B. garinii* performed best in neuroborreliosis (60 vs. 44%). The anti-OspC IgG response was less prominent than the IgM response and was infrequent in the late stages of the disease (0-20%). The benefit of combining the evaluation of anti-OspC responses with all three species was limited. The overall diagnostic sensitivity of WB anti-*B. garinii* OspC evaluation was, in the early stages of the disease, comparable to the results obtained using the flagellum ELISA. In erythema migrans and neuroborreliosis, the addn. of anti-OspC IgM to the flagellum ELISA increased the sensitivity by 15% and 10%, resp. It can, therefore, be concluded that OspC from *B. garinii* is a suitable OspC test **antigen**, and that supplementary use of OspC from other species adds little to the overall diagnostic sensitivity. An ELISA based on *B. garinii* OspC and native flagella seems currently the most promising concept for a future antibody test in early Lyme borreliosis.

L15 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:583277 HCAPLUS

DOCUMENT NUMBER: 123:138478

TITLE: Taxonomic classification of 29 *Borrelia burgdorferi* strains isolated from patients with Lyme borreliosis: A comparison of five different phenotypic and genotypic typing schemes

AUTHOR(S): Lebech, Anne-Mette; Hansen, Klaus; Wilske, Bettina; **Theisen, Michael**

CORPORATE SOURCE: Department Infection-Immunology, Statens Seruminstitut, Copenhagen, DK-2300, Den.

SOURCE: Med. Microbiol. Immunol. (1994), 183(6), 325-41  
CODEN: MMIYAO; ISSN: 0300-8584

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Twenty-nine European and North American *Borrelia burgdorferi* strains isolated from patients with Lyme borreliosis, were investigated by restriction fragment length polymorphism (RFLP) of two phylogenetically highly conserved chromosomal genes encoding flagellin (*fla*) and the p60 common **antigen** (CA), as well as of the plasmid-borne outer surface protein A (*ospA*) gene. RFLP of the *ospA*, *fla* and CA genes revealed five, two and four distinct subspecies-specific patterns, resp. RFLP classification of the *B. burgdorferi* strains was compared with four different classification schemes proposed by others: (i) mol. mass profile of OspA and OspB (Adam et al. [1]); (ii) OspA serotyping (Wilske et al. [34]); (iii) genomic fingerprinting on the central region of the *B. burgdorferi fla* gene (Picken [24]) and (iv) 16S rRNA signature nucleotide anal. (Marconi and Garon [19]). Results obtained with the different methods correlated highly. All strains classified as *B. burgdorferi sensu stricto* and *B. afzelii* could be unequivocally identified as one distinct group by all five typing methods. *B. garinii* isolates, however, were more heterogeneous and according to RFLP of the CA and *ospA* gene fell into either two or three subgroups. The agreement of the different approaches supports the recent concept that *B. burgdorferi sensu lato* strains should be delineated to three genomic groups and that *B. burgdorferi sensu lato* is clonal. All 12 US strains were *B. burgdorferi sensu stricto*, whereas the 17 European isolates belonged to any of three genospecies. Among European *B. burgdorferi* isolates there was an assocn. between *B. burgdorferi* genospecies and the clin. manifestation of Lyme borreliosis. *B. afzelii* strains were found to predominate in 11 skin isolates (75%), whereas all 6 cerebrospinal fluid isolates from patients with neuroborreliosis were *B. garinii*. These findings support the concept of a strain-dependent organotropism of *B. burgdorferi*.

L15 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:431330 HCAPLUS

DOCUMENT NUMBER: 122:211558  
 TITLE: **Antigenicity** and immunogenicity of recombinant glutamate-rich protein of *Plasmodium falciparum* expressed in *Escherichia coli*  
 AUTHOR(S): **Theisen, Michael**; Vuust, Jens; Gottschau, Adam; Jepsen, Soeren; Hoegh, Birthe  
 CORPORATE SOURCE: Department Infection-Immunology, Statens Seruminstitut, Copenhagen, DK-2300, Den.  
 SOURCE: Clin. Diagn. Lab. Immunol. (1995), 2(1), 30-4  
 CODEN: CDIMEN; ISSN: 1071-412X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB A recombinant *Plasmodium falciparum* glutamate-rich protein (GLURP) was produced in *Escherichia coli* as a nearly full-length protein. To map immunodominant regions on GLURP, the non-repetitive N-terminal region (R0) as well as the central repeat region (R1) and the C-terminal repeat region (R2) were also produced as sep. products. All four purified gene products reacted specifically with serum samples from adults living in an area of Liberia where malaria is holoendemic. It appears that the human immune response against GLURP is primarily directed against the R2 region because 94% of the serum samples reacted with this region in an immunoassay. Antibody reactivity against the R0 region was also obsd. in 75% of the serum samples, while the R1 region showed only weak antibody-binding activity. When the nearly full-length GLURP mol. was adsorbed to Al(OH)<sub>3</sub> it was immunogenic in mice. In these expts., the antibody response was almost exclusively directed against the R2 region. When anti-GLURP sera were obtained from rabbits immunized with the three regions, R0, R1, and R2, resp., they recognized in immunopptn. expts. authentic GLURP from *P. falciparum* grown in vitro. These results demonstrate that GLURP produced in *E. coli* can induce a humoral immune response against GLURP derived from blood-stage parasites.

L15 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1994:262492 HCAPLUS  
 DOCUMENT NUMBER: 120:262492  
 TITLE: Polymorphism in ospC gene of *Borrelia burgdorferi* and immunoreactivity of OspC protein: implications for taxonomy and for use of OspC protein as a diagnostic antigen  
 AUTHOR(S): **Theisen, Michael**; Frederiksen, Birgitte; Lebech, Anne Mette; Vuust, Jens; Hansen, Klaus  
 CORPORATE SOURCE: Dep. Infect. Immunol., Statens Seruminst., Copenhagen, DK-2300, Den.  
 SOURCE: J. Clin. Microbiol. (1993), 31(10), 2570-6  
 CODEN: JCMIDW; ISSN: 0095-1137  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The nucleotide sequences of the ospC gene from five Danish human *Borrelia burgdorferi* isolates representing all three *B. burgdorferi* genospecies (*B. burgdorferi sensu stricto*, *Borrelia garinii* sp. nov., and group VS461) and from the American type strain B31 were detd. and compared with the published ospC sequence from the German *B. burgdorferi* isolate PKo (R. Fuchs, S. Jauris, F. Lottspeich, V. Preac-Mursic, B. Wilske, and E. Soutschek, Mol. Microbiol. 6:503-509, 1992). The ospC gene was present in all isolates, regardless of the presence or absence of its product, OspC. The deduced amino acid sequences of OspC from the seven isolates were aligned and revealed pairwise sequence identities ranging from 60.5 to 100%. Differences were scattered throughout the amino acid sequences. A phylogenetic tree was constructed and revealed three distinct phenotypic groups OspCI to OspCIII corresponding to the three delineated genospecies. Immunoblot anal. revealed that the seven OspC proteins tested have both common and specific epitopes. There is significant epitope diversity, since even polyclonal antisera showed serotype-restricted specificity.

Therefore, a serodiagnostic assay for Lyme borreliosis utilizing OspC as a test **antigen** should include all three OspC phenotypes in order to obtain a species-wide sensitivity.

L15 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:161622 HCAPLUS  
 DOCUMENT NUMBER: 120:161622  
 TITLE: **Antigenic** proteins of Haemophilus somnus for use in vaccines and cloning and expression of genes encoding them  
 INVENTOR(S): Potter, Andrew A.; Pontarollo, Reno A.; Pfeiffer, Cheryl G.; **Theisen, Michael**; Harland, Richard J.; Rioux, Clement  
 PATENT ASSIGNEE(S): University of Saskatchewan, Can.  
 SOURCE: PCT Int. Appl., 120 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9321323	A1	19931028	WO 1993-CA135	19930405
W: AU, CA, HU, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9338838	A1	19931118	AU 1993-38838	19930405
EP 635055	A1	19950125	EP 1993-907710	19930405
EP 635055	B1	19981223		
R: DE, FR, GB				
US 6100066	A	20000808	US 1996-619812	19960315
PRIORITY APPLN. INFO.:				
			US 1992-865050	A 19920409
			US 1992-893424	A 19920604
			US 1992-893426	A 19920604
			US 1993-38287	A 19930329
			US 1993-38288	A 19930329
			US 1993-38719	A 19930329
			WO 1993-CA135	A 19930405

AB **Antigenic** proteins of Haemophilus somnus including the hemin-binding protein, the hemolysin, and the LppB and LppC proteins are obtained. The proteins are used in vaccines and may be manufd. by heterologous expression of the cloned genes. The genes for the hemin-binding protein (hmb) and the hemolysin (hly) were cloned from a Sau3A partial digest library in pHC79 by screening for activity and the genes subcloned by std. methods. Similarly, several other genes were cloned by screening for activity, including LppA; this gene was cloned from a Sau 3A partial library in the expression vector pGH433 by screening with hyperimmune serum. The LppB gene was cloned by its conferring of Congo Red binding activity. The LppA and LppB proteins manufd. using these clones were extd. from inclusion bodies and incorporated into vaccines with Emulsigen Plus to give 2 mL preps. contg. 100 .mu.g **antigen** and 33 vol.% adjuvant. Calves were innoculated twice at three week intervals with 2 mL of vaccine (LppA, or LppB, or LppA+LppB, or placebo) and the titers of antibodies showed that both proteins were **antigenic** and did not interfere with one another. The vaccinated animals showed less severe symptoms upon challenge with 108 cfu of H. somnus.

L15 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1993:464572 HCAPLUS  
 DOCUMENT NUMBER: 119:64572  
 TITLE: Molecular cloning, nucleotide sequence, and characterization of lppB, encoding an

**antigenic** 40-kilodalton lipoprotein of *Haemophilus somnus*

AUTHOR(S): **Theisen, Michael**; Rioux, Clement R.; Potter, Andrew A.

CORPORATE SOURCE: Vet. Infect. Dis. Organ., Univ. Saskatchewan, Saskatoon, SK, S7N 0W0, Can.

SOURCE: Infect. Immun. (1993), 61(5), 1793-8  
CODEN: INFIBR; ISSN: 0019-9567

DOCUMENT TYPE: Journal

LANGUAGE: English

AB *Hemopholus somnus* is a facultative intracellular pathogen which causes a wide range of diseases in cattle. To identify putative virulence determinants, a genomic library of *H. somnus* in *Escherichia coli* was screened for Congo red binding, a property assocd. with virulence in pathogenic bacteria, and subsequently with bovine hyperimmune sera raised against *H. somnus* HS25. A Congo red-binding clone carrying a 1.8-kb DNA insert was found to encode a strongly seroreactive LppB protein with an apparent mol. wt. of 40,000. The nucleotide sequence of the entire DNA insert was detd. Two open reading frames coding for polypeptides with calcd. mol. wts. of 21,893 and 30,721 were identified. The larger open reading frame encoded LppB, while the smaller reading frame encoded a nonseroreactive protein with a relative mol. mass of approx. 18 kDa. The 16 amino-terminal amino acids of the deduced LppB polypeptide showed strong sequence homol. to the signal peptide of secreted bacterial proteins, and the sequence Leu-Ala-Ala-Cys at the putative cleavage site corresponds to the consensus cleavage sequence of bacterial lipoproteins. Synthesis of the mature LppB lipoprotein in *H. somnus* was inhibited by globomycin, a specific inhibitor of signal peptidase II. LppB was localized to the outer membrane of *H. somnus*.

L15 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1993:189453 HCAPLUS

DOCUMENT NUMBER: 118:189453

TITLE: Molecular cloning, nucleotide sequence, and characterization of a 40,000-molecular-weight lipoprotein of *Haemophilus somnus*

AUTHOR(S): **Theisen, Michael**; Rioux, Clement R.; Potter, Andrew A.

CORPORATE SOURCE: Vet. Infect. Dis. Organ., Univ. Saskatchewan, Saskatoon, SK, S7N 0W0, Can.

SOURCE: Infect. Immun. (1992), 60(3), 826-31  
CODEN: INFIBR; ISSN: 0019-9567

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A gene of *H. somnus* encoding the major 40,000-mol.-wt. **antigen** (LppA) was cloned on a 2-kb *SauAI* fragment. The nucleotide sequence of the entire DNA insert was detd. One open reading frame, encoding a 247-residue polypeptide with a calcd. mol. wt. of 27,072, was identified. This reading frame was confirmed by sequencing the fusion joint of two independent *lppA::TnphoA* gene fusions. The 21 N-terminal amino acids of the deduced polypeptide showed strong sequence homol. to the signal peptide of secreted proteins, and the sequence Leu-Leu-Ala-Ala-Cys at the putative cleavage site is identical to the consensus cleavage sequence of lipoproteins from gram-neg. bacteria. The presence of the lipid moiety on the protein was shown by incorporation of radioactive palmitic acid into the natural *H. somnus* protein. Palmitic acid could also be incorporated into the recombinant protein in *Escherichia coli*. Synthesis of the mature LppA lipoprotein was inhibited by globomycin, showing that cleavage of the signal peptide is mediated by signal peptidase II in both organisms. By using site-directed mutagenesis, the cysteine residue at the cleavage site was changed to glycine. Radiolabeled palmitate was not incorporated into the mutated protein, showing that lipid modification occurs at the Cys-22 residue.

L15 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1993:53322 HCAPLUS

DOCUMENT NUMBER: 118:53322

TITLE: Cloning, sequencing, expression, and functional studies of a 15,000-molecular-weight Haemophilus somnus **antigen** similar to Escherichia coli ribosomal protein S9

AUTHOR(S): Theisen, Michael; Potter, Andrew A.

CORPORATE SOURCE: Univ. Saskatchewan, Saskatoon, SK, S7N 0W0, Can.

SOURCE: J. Bacteriol. (1992), 174(1), 17-23

CODEN: JOBAAY; ISSN: 0021-9193

DOCUMENT TYPE: Journal

LANGUAGE: English

AB H. somnus is a gram-neg. bacterium capable of causing a no. of disease syndromes in cattle. This article describes the cloning and characterization of a gene coding for a 15,000-mol.-wt. (15K) polypeptide which reacts strongly with antiserum against H. somnus. Anal. of plasmid-encoded polypeptides by polyacrylamide gel electrophoresis showed that the corresponding gene is the second in a transcriptional unit. The first gene codes for a protein with a mol. wt. of approx. 17,000. Using antiserum against the two recombinant proteins, the authors could show that the natural proteins are predominantly present in purified ribosomes from H. somnus. The nucleotide sequence of both genes and flanking regions has been detd., and the deduced amino acid sequence of the two polypeptides was used to search for sequence homol. in the GenBank data base. The 15K polypeptide showed 89% similarity to the E. coli ribosomal protein S9, and the 17K polypeptide showed 94% similarity to the E. coli ribosomal protein L13. In E. coli, the corresponding genes constitute a bicistronic operon, with the same gene order as that found in H. somnus. A plasmid expressing the 15K protein was found to complement an E. coli rpsI mutation. When a frameshift mutation was introduced into the 15K protein gene, the resulting plasmid failed to complement this rpsI mutation, demonstrating functional homol. between the 15K protein and S9 from E. coli. Downstream from the 15K protein gene is located another open reading frame, which could code for a polypeptide with a predicted mol. wt. of 24,427. A protein with a similar mol. wt. was detected in minicells contg. the recombinant clone. This polypeptide is 69% similar to the stringent starvation protein (Ssp) of E. coli.

=&gt;

=&gt;

=&gt; d stat que 116

L7 63 SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLM A"/AU OR "HOLM A"/IN)  
 L8 146 SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLM ARNE"/AU OR "HOLM ARNE"/IN)  
 L9 10 SEA FILE=HCAPLUS ABB=ON PLU=ON "JORGENSEN R"/AU OR "JORGENSEN R M"/AU OR "JORGENSEN RIKKE MALENE"/AU OR "JORGENSEN RIKKE MALENE"/IN  
 L10 19 SEA FILE=HCAPLUS ABB=ON PLU=ON "OSTERGAARD S"/AU OR ("OSTERGAARD SOREN"/AU OR "OSTERGAARD SOREN"/IN)  
 L11 45 SEA FILE=HCAPLUS ABB=ON PLU=ON ("THEISEN M"/AU OR "THEISEN M"/IN OR "THEISEN M J"/AU OR "THEISEN M O"/AU) OR ("THEISEN MICHAEL"/AU OR "THEISEN MICHAEL"/IN OR "THEISEN MICHAEL J"/AU)  
 L12 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 NOT L10  
 L13 41 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 NOT (L10 OR L12)  
 L14 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L7 OR L8)  
 L15 19 SEA FILE=HCAPLUS ABB=ON PLU=ON (L13 AND (ANTIGEN? OR ASSEMBL? OR LPA? OR LIGAND? OR (AMINO(W)ACID? OR AA OR PEPTIDE OR PROTEIN) (W)SYSTEM?)) NOT L14  
 L16 27 SEA FILE=HCAPLUS ABB=ON PLU=ON ((L7 OR L8) AND (ANTIGEN? OR

ASSEMBL? OR LPA? OR LIGAND? OR (AMINO(W)ACID? OR AA OR PEPTIDE  
OR PROTEIN) (W)SYSTEM?) NOT (L10 OR L12 OR L15 OR L14)

=&gt;

=&gt;

=&gt; d ibib abs tot l16

L16 ANSWER 1 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:831539 HCAPLUS  
DOCUMENT NUMBER: 134:84820  
TITLE: Longer peptide can be accommodated in the MHC class I  
binding site by a protrusion mechanism  
AUTHOR(S): Stryhn, Anette; Pedersen, Lars Ostergaard; **Holm;**  
**Arne;** Buus, Soren  
CORPORATE SOURCE: Institute of Medical Microbiology and Immunology,  
University of Copenhagen, Copenhagen, Den.  
SOURCE: Eur. J. Immunol. (2000), 30(11), 3089-3099  
CODEN: EJIMAF; ISSN: 0014-2980  
PUBLISHER: Wiley-VCH Verlag GmbH  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB According to current consensus, CD8+ T cell responses are focused upon short peptide sequences (8-11 amino acids) presented by MHC class I mols. This size restriction is thought to operate mostly at the level of peptide-MHC class I interaction. Crystal structures have shown that the free N and C termini of a bound peptide interact through hydrogen bonding networks to conserved residues at either end of the class I binding site. Accordingly, it is thought that the termini are fixed and that only minor variations in peptide size are possible through a central bulging mechanism. We find that this consensus view is not always correct as some peptide-MHC class I interaction will accept significant extensions. Furthermore, our results indicate that in some cases protrusion, rather than bulging, may be the mechanism of extension. Depending upon the particular peptide-MHC combination in question, such extensions can occur at either the N or C terminus (but never both at the same time). Finally, we show that MHC and T cell in some cases can detect the identity of the extension, i.e. that extensions may be part of the specificity of the T cell immune response. We suggest that such extensions may play a physiol. role.

REFERENCE COUNT: 28  
REFERENCE(S): (1) Bouvier, M; Science 1994, V265, P398 HCAPLUS  
(2) Buus, S; Biochim Biophys Acta 1995, V1243, P453 HCAPLUS  
(3) Buus, S; Cell 1986, V47, P1071 HCAPLUS  
(4) Collins, E; Nature 1994, V371, P626 HCAPLUS  
(6) Fremont, D; Science 1992, V257, P919 HCAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:514662 HCAPLUS  
DOCUMENT NUMBER: 133:172364  
TITLE: Neurite outgrowth induced by a synthetic peptide  
**ligand** of neural cell adhesion molecule  
requires fibroblast growth factor receptor activation  
AUTHOR(S): Ronn, Lars C. B.; Doherty, Patrick; **Holm, Arne**  
; Berezin, Vladimir; Bock, Elisabeth  
CORPORATE SOURCE: The Protein Laboratory, Institute of Molecular  
Pathology, Panum Institute, Copenhagen, DK-2200, Den.  
SOURCE: J. Neurochem. (2000), 75(2), 665-671  
CODEN: JONRA9; ISSN: 0022-3042  
PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The neural cell adhesion mol. NCAM is involved in axonal outgrowth and target recognition in the developing nervous system. In vitro, NCAM-NCAM binding has been shown to induce neurite outgrowth, presumably through an activation of fibroblast growth factor receptors (FGFRs). The authors have recently identified a neuritogenic **ligand**, termed the C3 peptide, of the first Ig module of NCAM using a combinatorial library of synthetic peptides. Here the authors investigate whether stimulation of neurite outgrowth by this synthetic **ligand** of NCAM involves FGFRs. In primary cultures of cerebellar neurons from wild-type mice, the C3 peptide stimulated neurite outgrowth. This response was virtually absent in cultures of cerebellar neurons from transgenic mice expressing a dominant-neg. form of the FGFR1. Likewise, in PC12E2 cells transiently expressing a dominant-neg. form of the mouse FGFR1, induction of neurites by the C3 peptide was abrogated. These findings suggest that the neuritogenic effect of the C3 peptide requires the presence of functional FGFRs and support the hypothesis that FGFRs are essential in cell adhesion mol.-stimulated neurite outgrowth. The C3 peptide appears to stimulate neurite outgrowth by specifically activating an NCAM-FGFR-dependent signaling cascade and may therefore be of considerable interest as a tool for the detn. of NCAM-dependent neurite outgrowth as well as a potential drug capable of promoting outgrowth and regeneration of NCAM-responsive axons.

REFERENCE COUNT: 27

REFERENCE(S): (1) Atkins, A; FEBS Lett 1999, V451, P162 HCAPLUS  
 (2) Covault, J; Proc Natl Acad Sci USA 1985, V82, P4544 HCAPLUS  
 (3) Cremer, H; Nature 1994, V367, P455 HCAPLUS  
 (4) Cremer, H; Proc Natl Acad Sci USA 1998, V95, P13242 HCAPLUS  
 (5) Doherty, P; Mol Cell Neurosci 1996, V8, P99 HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:411590 HCAPLUS  
 DOCUMENT NUMBER: 133:148866  
 TITLE: Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 **antigen**  
 AUTHOR(S): Olsen, Anja Weinreich; Hansen, Paul Robert; **Holm, Arne**; Andersen, Peter  
 CORPORATE SOURCE: Department of TB Immunology, Statens Serum Institute, Copenhagen, Den.  
 SOURCE: Eur. J. Immunol. (2000), 30(6), 1724-1732  
 CODEN: EJIMAF; ISSN: 0014-2980  
 PUBLISHER: Wiley-VCH Verlag GmbH  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB We have investigated the vaccine potential of two peptides derived from the 6-kDa early secretory **antigenic** target (ESAT)-6 **antigen** in the mouse model of tuberculosis. The peptides were both strongly immunogenic in B6CBAF1 (H-2b,k) mice and primed recall responses of the same intensity after immunization. However, both tuberculosis infection and immunization with ESAT-6 resulted in responses focused towards ESAT-61-20. Multiple **antigen** peptide constructs as well as free peptides were emulsified with di-Me dioctadecylammonium bromide/monophosphoryl lipid A/IL-2 and tested as exptl. vaccines in an i.v. and aerosol model of tuberculosis in mice. The peptide were highly immunogenic and induced cellular responses of the same magnitude. However, only vaccines based on the subdominant ESAT-651-70 epitope promoted significant levels of protective immunity and the level of



protection was equiv. to that achieved with ESAT-6 and BCG. These findings demonstrate the potential of peptide-based vaccines against tuberculosis and indicate that there is not direct correlation between the hierarchy of response to naturally processed peptides and their ability to induce protective immunity against Mycobacterium tuberculosis.

REFERENCE COUNT: 44  
 REFERENCE(S): (1) Adorini, L; J Exp Med 1988, V168, P2091 HCAPLUS  
 (2) Andersen, P; Infect Immun 1991, V59, P1558 HCAPLUS  
 (3) Andersen, P; Infect Immun 1991, V59, P1905 HCAPLUS  
 (4) Andersen, P; Infect Immun 1994, V62, P2536 HCAPLUS  
 (5) Andersen, P; J Immunol 1995, V154, P3359 HCAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:44892 HCAPLUS  
 DOCUMENT NUMBER: 133:3434  
 TITLE: A stem peptide carrier for the immunogenic presentation of peptides  
 AUTHOR(S): Heegaard, Peter M. H.; Bog, Yang S.; Jakobsen, Palle H.; **Holm, Arne**  
 CORPORATE SOURCE: Dept. Biochemistry & Immunology, Danish Veterinary Laboratory, Copenhagen, 1790, Den.  
 SOURCE: Innovation Perspect. Solid Phase Synth. Comb. Libr., Collect. Pap., Int. Symp., 5th (1999), Meeting Date 1997, 143-146. Editor(s): Epton, Roger. Mayflower Scientific Ltd.: Kingswinford, UK.  
 CODEN: 68OEAA  
 DOCUMENT TYPE: Conference  
 LANGUAGE: English

AB The authors have prepd. a simple, short lipopeptide carrier, the stem peptide, which is synthesized by std. Fmoc chem. and used for side-chain presentation of peptides, giving rise to side-chain peptide-specific antibodies by immunization without the inclusion of a carrier protein. The data indicate that even the use of adjuvant may not always be necessary. The stem peptide is an alternative to dendritic peptide carriers, and leads to highly defined, sol. and conformationally stabilized peptide immunogens. Here, to investigate the immunogenicity of the branched constructs, a 21 amino acid malarial peptide from the erythrocyte-binding protein (EBA) involved in erythrocyte invasion was coupled to a stem peptide carrier and then used to immunize mice. Esp. together with Freund's adjuvant, the derivatized carrier induced the prodn. of high levels of branch-peptide specific antibodies after immunization.

REFERENCE COUNT: 7  
 REFERENCE(S): (2) Metzger, J; Int J Pept Prot Res 1991, V37, P46 HCAPLUS  
 (3) Mutter, M; Trend Biochem Sci 1988, V13, P260 HCAPLUS  
 (4) O'Shea, E; Science 1991, V254, P539 HCAPLUS  
 (5) Tam, J; Proc Natl Acad Sci 1988, V85, P5409 HCAPLUS  
 (6) van Regenmortel, M; Synthetic Polypeptides as Antigens 1988, P95 HCAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:6214 HCAPLUS  
 DOCUMENT NUMBER: 132:320872  
 TITLE: A highly efficient, universal and unbiased approach to address MHC specificity. Quantitation by peptide libraries and improved prediction of binding  
 AUTHOR(S): Stryhn, A.; Pedersen, L. Ostergaard; Romme, T.; Bisgaard Holm, C.; **Holm, A.**; Buus, S.  
 CORPORATE SOURCE: Department of Experimental Immunology, University of

SOURCE: Copenhagen, Copenhagen, 2200, Den.  
 HLA: [Proc. Int. Histocompat. Workshop Conf.], 12th (1997), Meeting Date 1996, Volume 2, 435-438.  
 Editor(s): Charron, Dominique. EDK, Medical and Scientific International Publisher: Sevres, Fr.  
 CODEN: 68MRA5

DOCUMENT TYPE: Conference  
 LANGUAGE: English

AB Highly efficient, universal and unbiased approach to address MHC specificity by positional scanning combinatorial peptide libraries (PSCPL) was studied. The influenza virus hemagglutinin octamer peptide Ha (255-262) (FESTGNLI) was studied to investigate the specificity of H-2Kk by replacing each aminoacid by other aminoacids. Most of the substitutions had marginal effects on binding except that a replacement, at position 2 and 8 has significant deleterious effects.

REFERENCE COUNT: 10

REFERENCE(S): (1) Babbitt, B; Nature 1985, V317, P359 HCAPLUS  
 (2) Buus, S; Biochim Biophys Acta 1995, V1243, P453 HCAPLUS  
 (4) Falk, K; Nature 1991, V351, P290 HCAPLUS  
 (5) Gould, K; J Virol 1991, V65, P5401 HCAPLUS  
 (6) Olsen, A; Eur J Immunol 1994, V24, P385 HCAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:629645 HCAPLUS  
 DOCUMENT NUMBER: 132:1371  
 TITLE: Predicting Binding Affinities of Protein **Ligands** from Three-Dimensional Models: Application to Peptide Binding to Class I Major Histocompatibility Proteins

AUTHOR(S): Rognan, Didier; Lauemoller, Sanne Lise; **Holm, Arne**; Buus, Soren; Tschinke, Vincenzo

CORPORATE SOURCE: Department of Pharmacy, Swiss Federal Institute of Technology, Zurich, CH-8057, Switz.

SOURCE: J. Med. Chem. (1999), 42(22), 4650-4658  
 CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB A simple and fast free energy scoring function (Fresno) has been developed to predict the binding free energy of peptides to class I major histocompatibility (MHC) proteins. It differs from existing scoring functions mainly by the explicit treatment of **ligand** desolvation and of unfavorable protein-**ligand** contacts. Thus, it may be particularly useful in predicting binding affinities from three-dimensional models of protein-**ligand** complexes. The Fresno function was independently calibrated for two different training sets: (a) five HLA-A\*0201-peptide structures, which had been detd. by X-ray crystallog., and (b) three-dimensional models of 37 H-2Kk-peptide structures, which had been obtained by knowledge-based homol. modeling. For both training sets, a good cross-validated fit to exptl. binding free energies was obtained with predictive errors of 3-3.5 kJ/mol. As expected, lipophilic interactions were found to contribute the most to HLA-A\*0201-peptide interactions, whereas H-bonding predominates in H-2Kk recognition. Both cross-validated models were afterward used to predict the binding affinity of a test set of 26 peptides to HLA-A\*0204 (an HLA allele closely related to HLA-A\*0201) and of a series of 16 peptides to H-2Kk. Predictions were more accurate for HLA-A2-binding peptides as the training set had been built from exptl. detd. structures. The av. error in predicting the binding free energy of the test peptides was 3.1 kJ/mol. For the homol. model-derived equation, the av. error in predicting the binding free energy of peptides to Kk was significantly higher (5.4

kJ/mol) but still very acceptable. The present scoring function is thus able to predict with a good accuracy binding free energies from three-dimensional models, at the condition that the backbone coordinates of the MHC-bound peptide have first been detd. with an accuracy of about 1-1.5 .ANG.. Furthermore, it may be easily re-calibrated for any protein-ligand complex.

REFERENCE COUNT:

67

REFERENCE(S):

- (1) Altuvia, Y; Hum Immunol 1997, V58, P1 HCAPLUS
- (2) Altuvia, Y; J Mol Biol 1995, V249, P244 HCAPLUS
- (4) Arnett, K; Tissue Antigens 1995, V46, P217 HCAPLUS
- (5) Batalia, M; Biopolymers 1997, V43, P281 HCAPLUS
- (8) Bohm, H; J Comput-Aided Mol Des 1998, V12, P309 HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:186738 HCAPLUS

DOCUMENT NUMBER: 131:30773

TITLE: Human T cell responses to the ESAT-6 **antigen** from Mycobacterium tuberculosis

AUTHOR(S): Ravn, Pernille; Demissie, Abebech; Equale, Tewodros; Wondwosson, Hailu; Lein, David; Amoudy, Hanady A.; Mustafa, Abu S.; Jensen, Axel Kok; **Holm, Arne**; Rosenkrands, Ida; Oftung, Fredrik; Olobo, Joseph; Von Reyn, Fordham; Andersen, Peter

CORPORATE SOURCE: Department of Tuberculosis Immunology, Statens Seruminstitut, Department of Pulmonary Medicine, Rigshospitalet, Royal Veterinary and Agricultural University, Copenhagen, Den.

SOURCE: J. Infect. Dis. (1999), 179(3), 637-645

CODEN: JIDIAQ; ISSN: 0022-1899

PUBLISHER: University of Chicago Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Human T cell responses to ESAT-6 and eight synthetic overlapping peptides were investigated in tuberculosis (TB) patients and control subjects from regions of high and low endemicity for TB. ESAT-6 was recognized by 65% of all tuberculin purified protein deriv.-responsive TB patients, whereas only 2 of 29 bacille Calmette-Guerin-vaccinated Danish healthy donors recognized this mol. In Ethiopia, a high frequency (58%) of healthy contacts of TB patients recognized ESAT-6. All of the peptides were recognized by some donors, indicating that the mol. holds multiple epitopes. Danish and Ethiopian patients differed in the fine specificity of their peptide responses. Recognition of the C-terminal region (aa 72-95) was predominant in Danish patients, whereas recognition of aa 42-75 was predominant in Ethiopia. The relationship of these differences to the distribution of HLA types in the two populations is discussed. This study demonstrates that ESAT-6 is frequently recognized during early infection and holds potential as a component of a future TB-specific diagnostic reagent.

REFERENCE COUNT:

47

REFERENCE(S):

- (1) Andersen, P; Infect Immun 1994, V62, P2536 HCAPLUS
- (2) Andersen, P; J Immunol 1995, V154, P3359 HCAPLUS
- (4) Boesen, H; Infect Immun 1995, V63, P1491 HCAPLUS
- (5) Brandt, L; J Immunol 1996, V157, P3527 HCAPLUS
- (7) Chiciz, R; J Exp Med 1993, V178, P27 HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:551331 HCAPLUS

DOCUMENT NUMBER: 129:259126

TITLE: The P9 pocket of HLA-DQ2 (non-Asp.beta.57) has no particular preference for negatively charged anchor

residues found in other type 1 diabetes-predisposing non-Asp.beta.57 MHC class II molecules

AUTHOR(S): Quarsten, Hanne; Paulsen, Gunnar; Johansen, Bente H.; Thorpe, Christopher J.; **Holm, Arne**; Buus, Soren; Solid, Ludvig M.

CORPORATE SOURCE: Inst. of Transplantation Immunology, Rikshospitalet, Univ. of Oslo, Oslo, 0027, Norway

SOURCE: Int. Immunol. (1998), 10(8), 1229-1236  
CODEN: INIMEN; ISSN: 0953-8178

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Susceptibility and resistance to type 1 diabetes are assocd. with MHC class II alleles that carry non-Asp and Asp at residue 57 of their .beta. chain resp. The effect of Asp or non-Asp.beta.57 may relate to a differential ability of distinct class II mols. to bind specific immuno-pathogenic peptides. Recent studies in man and mouse have revealed that some type 1 diabetes-predisposing non-Asp.beta.57 class II mols. (i.e. DQ8, DR4Dw15 and I-Ag7) preferentially bind peptides with a neg. charged anchor residue at P9. It has been suggested that this is a common feature of type 1 diabetes-predisposing class II mols. The mol. explanation for such a phenomenon could be that class II .beta. chains with Asp.beta.57 form a salt bridge between Asp.beta.57 and a conserved Arg of the .alpha. chain, whereas in non-Asp.beta.57 mols. the Arg is unopposed and free to interact with neg. charged P9 peptide anchor residues. The authors have investigated the specificity of the P9 pocket of the type 1 diabetes-assocd. DQ2 mol. and in particular examd. for charge effects at this anchor position. Different approaches were undertaken. The authors analyzed binding of a high-affinity binding **ligand** and P9-substituted variants of this peptide, and the authors analyzed the binding of a set of synthetic random peptide libraries. The binding analyses were performed with wild-type DQ2 and a mutated DQ2 with Ala at .beta.57 substituted with Asp. The authors' results indicate that the wild-type DQ2 (non-Asp.beta.57) prefers large hydrophobic residues at P9 and that there is no particular preference for binding peptides with neg. charged residues at this position. The specificity of the P9 pocket in the mutated DQ mol. is altered, indicating that the .beta.57 residue contributes to detg. the specificity of the P9 pocket. The data do not lend support to the hypothesis that all non-Asp .beta.57 class II mols. predispose to development of disease by binding peptides with neg. charged P9 anchor residues.

L16 ANSWER 9 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:67789 HCAPLUS

DOCUMENT NUMBER: 128:179092

TITLE: B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis

AUTHOR(S): Harboe, Morten; Malin, Adam S.; Dockrell, Hazel S.; Wiker, Harald Gotten; Ulvund, Gunni; **Holm, Arne**; Jorgensen, Mikala Clok; Andersen, Peter

CORPORATE SOURCE: Institute of Immunology and Rheumatology, University of Oslo, Oslo, N-0172, Norway

SOURCE: Infect. Immun. (1998), 66(2), 717-723  
CODEN: INFIBR; ISSN: 0019-9567

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB ESAT-6 is an important T-cell **antigen** recognized by protective T cells in animal models of infection with Mycobacterium tuberculosis. In an ELISA with overlapping peptides spanning the sequence of ESAT-6, monoclonal antibody HYB76-8 reacted with two peptides in the N-terminal region of the mol. Assays with synthetic truncated peptides allowed a precise mapping of the epitope to the residues EQQWNFAGIEAAA at positions

3 to 15. Hydrophilicity plots revealed one hydrophilic area at the N terminus and two addnl. areas further along the polypeptide chain. Antipeptide antibodies were generated by immunization with synthetic 8-mer peptides corresponding to these two regions coupled to keyhole limpet hemocyanin. Prolonged immunization with a 23-mer peptide (positions 40 to 62) resulted in the formation of antibodies reacting with the peptide as well as native ESAT-6. A double-antibody ELISA was then developed with monoclonal antibody HYB76-8 as a capture antibody, **antigen** for testing in the second layer, and antipeptide antibody in the third layer. The assay was suitable for quantification of ESAT-6 in *M. tuberculosis* **antigen** prepns., showing no reactivity with *M. bovis* BCG Tokyo culture fluid, used as a neg. control, or with MPT64 or **antigen** 85B, previously shown to cross-react with HYB76-8. This capture ELISA permitted the identification of ESAT-6 expression from vaccinia virus constructs contg. the *esat-6* gene; this expression could not be identified by std. immunoblotting.

L16 ANSWER 10 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:472462 HCAPLUS  
 DOCUMENT NUMBER: 127:160185  
 TITLE: MHC class I binding motifs: an unbiased quantitative approach to motif definition  
 AUTHOR(S): Stryhn, Anette; Pedersen, Lars Oestegaard; Romme, Tina; Holm, Charlotte Bisgaard; **Holm, Arne**; Buus, Soeren  
 CORPORATE SOURCE: Institute of Medical Microbiology and Immunology, University of Copenhagen, Copenhagen, Den.  
 SOURCE: Alfred Benzon Symp. (1997), 40(HLA and Disease: The Molecular Basis), 133-147  
 CODEN: ABSYB2; ISSN: 0105-3639  
 PUBLISHER: Munksgaard  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English

AB A review and discussion, with 40 refs., on MHC restriction, MHC polymorphism, MHC specificity, motif identification, hemagglutinin peptide 255-262 binding to Kk, positional scanning combinatorial peptide libraries (PSCPL), predictions based on the PSCPL approach, and complete mapping of all human MHC specificities.

L16 ANSWER 11 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:364667 HCAPLUS  
 DOCUMENT NUMBER: 127:32565  
 TITLE: Characterization of the delayed type hypersensitivity-inducing epitope of MPT64 from *Mycobacterium tuberculosis*  
 AUTHOR(S): Oettinger, T.; **Holm, A.**; Hasloev, K.  
 CORPORATE SOURCE: TB Research Unit, Department of Mycobacteriology, Statens Serum Institut, Copenhagen, DK-2300, Den.  
 SOURCE: Scand. J. Immunol. (1997), 45(5), 499-503  
 CODEN: SJIMAX; ISSN: 0300-9475  
 PUBLISHER: Blackwell  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB *Mycobacterium tuberculosis* secretes several proteins into the extracellular environment, some of which are restricted to the *M. tuberculosis* complex. One of these **antigens** is MPT64. Recently, the authors showed that native as well as recombinant MPT64 is able to distinguish between an *M. tuberculosis* infection and a BCG Danish 1331 vaccination. Improved distinction between tuberculin purified protein deriv. (PPD) sensitivity conferred by an *M. tuberculosis* infection and that induced by a BCG vaccination or infection with environmental mycobacteria would be useful in the control of tuberculosis. In this study, the authors report the mapping and characterization of a

Dth-inducing epitope by the use of synthetic peptides in guinea-pigs vaccinated with BCG Danish 1331 or Tokyo. Studies with overlapping synthetic peptides have pinpointed the biol. activity to a single Dth-inducing epitope at the C-terminal region of MPT64 consisting of 15 residues between amino acids Gly-173 and Ala-187, the core epitope (CE15). A fine mapping using truncated versions of CE15 indicates the epitope is restricted to 13 residues between amino acids Val-174 to Glu-186. However, the optimal Dth reactivity is obtained by CE15. Different modifications of CE15 revealed that a lysine tree construction improves the skin reactivity to a max. level approaching that of the reactivity to tuberculin PPD.

L16 ANSWER 12 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1996:632476 HCAPLUS

DOCUMENT NUMBER: 125:325659

TITLE: Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis

AUTHOR(S): Brandt, Lise; Oettinger, Thomas; Holm, Arne; Andersen, Aase B.; Andersen, Peter

CORPORATE SOURCE: Bacterial Vaccine and Mycobacteria Dep., Royal Veterinary and Agricultural Univ., Copenhagen, Den.

SOURCE: J. Immunol. (1996), 157(8), 3527-3533

CODEN: JOIMA3; ISSN: 0022-1767

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The recall of long-lived immunity in a mouse model of tuberculosis (TB) is defined as an accelerated accumulation of reactive T cells in the target organs. The authors have recently identified antigen (Ag) 85B and a 6-kDa early secretory antigenic target, designated ESAT-6, as key antigenic targets recognized by these cells. Here, preferential recognition of the ESAT-6 Ag during the recall of immunity was shared by 5 of 6 genetically different strains of mice. Overlapping peptides spanning the sequence of ESAT-6 were used to map 2 T cell epitopes on this mol. One epitope recognized in the context of H-2b,d was located in the N-terminal part of the mol., whereas an epitope recognized in the context of H-2a,k covered amino acids 51-60. Shorter versions of the N-terminal epitope allowed the precise definition of a 13-amino acid core sequence recognized in the context of H-2b. The peptide covering the N-terminal epitope was immunogenic, and a T cell response with the same fine specificity as that induced during TB infection was generated by immunization with the peptide in IFA. In the C57BL/6j strain, this single epitope was recognized by an exceedingly high frequency of splenic T cells (.apprx.1:1000), representing 25-35% of the total culture filtrate-reactive T cells recruited to the site of infection during the first phase of the recall response. These findings emphasize the relevance of this Ag in the immune response to TB and suggest that immunol. recognition in the first phase of infection is a highly restricted event dominated by a limited no. of T cell clones.

L16 ANSWER 13 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1996:575785 HCAPLUS

DOCUMENT NUMBER: 125:219078

TITLE: Shared fine specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex

AUTHOR(S): Stryhn, Anette; Andersen, Peter S.; Pedersen, Lars Oe.; Svejgaard, Arne; Holm, Arne; Thorpe, Christopher J.; Fugger, Lars; Buus, Soeren; Engberg, Jan

CORPORATE SOURCE: Institute Medical Microbiol. and Immunology, Univ. Copenhagen, Copenhagen, Den.

SOURCE: Proc. Natl. Acad. Sci. U. S. A. (1996), 93(19),

10338-10342

CODEN: PNASA6; ISSN: 0027-8424

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB Cytotoxic T cells recognize mosaic structures consisting of target peptides embedded within self-major histocompatibility complex (MHC) class I mols. This structure has been described in great detail for several peptide-MHC complexes. In contrast, how T-cell receptors recognize peptide-MHC complexes have been less well characterized. We have used a complete set of singly substituted analogs of a mouse MHC class I, Kk-restricted peptide, influenza hemagglutinin (Ha)255-262, to address the binding specificity of this MHC mol. Using the same peptide-MHC complexes we detd. the fine specificity of two Ha255-262-specific, Kk-restricted T cells, and of a unique antibody, pSAN, specific for the same peptide-MHC complex. Independently, a model of the Ha255-262-Kk complex was generated through homol. modeling and mol. mechanics refinement. The functional data and the model corroborated each other showing that peptide residues 1, 3, 4, 6, and 7 were exposed on the MHC surface and recognized by the T cells. Thus, the majority, and perhaps all, of the side chains of the non-primary anchor residues may be available for T-cell recognition, and contribute to the stringent specificity of T cells. A striking similarity between the specificity of the T cells and that of the pSAN antibody was found and most of the peptide residues, which could be recognized by the T cells, could also be recognized by the antibody.

L16 ANSWER 14 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER:

1996:487229 HCAPLUS

DOCUMENT NUMBER:

125:165268

TITLE:

Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantification by peptide libraries and improved prediction of binding

AUTHOR(S):

Stryhn, Anette; Pedersen, Lars Oestegaard; Romme, Tina; Holm, Charlotte Bisgaard; **Holm, Arne;** Buus, Soeren

CORPORATE SOURCE:

Inst. Medical Microbiology, Univ. Copenhagen, Copenhagen, DK-2200, Den.

SOURCE:

Eur. J. Immunol. (1996), 26(8), 1911-1918  
CODEN: EJIMAF; ISSN: 0014-2980

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB Considerable interest has focused on understanding how major histocompatibility complex (MHC) specificity is generated and characterizing the specificity of MHC mols. with the ultimate goal being to predict peptide binding. We have used a strategy where all possible peptides of a particular size are distributed into positional scanning combinatorial peptide libraries (PSCPL) to develop a highly efficient, universal and unbiased approach to address MHC specificity. The PSCPL approach appeared qual. and quant. superior to other currently used strategies. The av. effect of any amino acid in each position was quantitated, allowing a detailed description of extended peptide binding motifs including primary and secondary anchor residues. It also identified disfavored residues which were found to be surprisingly important in shaping MHC class I specificity. Assuming that MHC class I specificity is the result of largely independently acting subsites, the binding of unknown peptides could be predicted. Conversely, this argues that MHC class I specificities consist of an array of subspecificities acting in a combinatorial mode.

L16 ANSWER 15 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER:

1996:129630 HCAPLUS

DOCUMENT NUMBER:

124:172920

TITLE: Characterization of two conformational epitopes of the  
Chlamydia trachomatis serovar L2 DnaK immunogen  
AUTHOR(S): Birkellund, Svend; Mygind, Per; **Holm, Arne**;  
Larsen, Bente; Beck, Frederik; Christiansen, Gunna  
CORPORATE SOURCE: Dep. of Medical Microbiology and Immunology, Univ. of  
Aarhus, Aarhus, DK-8000, Den.  
SOURCE: Infect. Immun. (1996), 64(3), 810-17  
CODEN: INFIBR; ISSN: 0019-9567

DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Chlamydia trachomatis DnaK is an important immunogen in chlamydial infections. DnaK is composed of a conserved N-terminal ATP-binding domain and a variable C-terminal peptide-binding domain. To locate the immunogenic part of C. trachomatis DnaK, we generated monoclonal antibodies (MAbs) against this protein. By use of recombinant DNA techniques, we located the epitopes for two MAbs in the C-terminal variable part. Although the antibodies reacted in an immunoblot assay, it was not possible to map the epitopes completely by use of 16-mer synthetic peptides displaced by one amino acid corresponding to the C-terminal part of C. trachomatis DnaK. To det. the limits of the epitopes, C. trachomatis DnaK and glutathione S-transferase fusion proteins were constructed and affinity purified. The purified DnaK fusion proteins were used for a fluid-phase inhibition ELISA with the two antibodies. The epitopes were found not to overlap. To obtain DnaK fragments recognized by the antibodies with the same affinity as native C. trachomatis DnaK, it was necessary to express, resp., regions of 127 and 77 amino acids. The MAbs described in this study thus recognized conformational epitopes of C. trachomatis DnaK.

L16 ANSWER 16 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1996:99500 HCAPLUS  
DOCUMENT NUMBER: 124:140406  
TITLE: Combinatorial peptide library and method  
INVENTOR(S): Hodges, Robert S.; Irvin, Randall T.; **Holm, Arne**; Wong, Wah Y.; Sheth, Hasmukh B.; Husband, Devon L.  
PATENT ASSIGNEE(S): S.P.I. Synthetic Peptides Inc., Can.  
SOURCE: PCT Int. Appl., 61 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9534575	A1	19951221	WO 1995-IB560	19950613
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5738996	A	19980414	US 1994-260199	19940615
AU 9528059	A1	19960105	AU 1995-28059	19950613
PRIORITY APPLN. INFO.:			US 1994-260199	A 19940615
			WO 1995-IB560	W 19950613

AB A combinatorial library compn. and method for using the library to construct oligomers effective to bind to a selected **ligand** is disclosed. The library compn. includes at least two sets of combinatorial oligomer libraries, each library set having selected oligomer subunit positions filled by known subunits, and other subunit positions contg. permutations of subunits. In the selection method, oligomers from each library set are identified, and a new permutation library formed of subunits corresponding to the highest binding affinity oligomers in each library is screened for binding affinity to the selected **ligand**.



L16 ANSWER 17 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:974613 HCAPLUS  
 DOCUMENT NUMBER: 124:53598  
 TITLE: Mapping of the delayed-type hypersensitivity-inducing epitope of secreted protein MPT64 from Mycobacterium tuberculosis  
 AUTHOR(S): Oettinger, Thomas; **Holm, Arne**; Mtoni, Isaac  
 M.; Andersen, Aase B.; Kasloev, Kaare  
 CORPORATE SOURCE: Mycobacteria Dept., Statens Serum Institut, Copenhagen, DK-2300, Den.  
 SOURCE: Infect. Immun. (1995), 63(12), 4613-18  
 CODEN: INFIBR; ISSN: 0019-9567  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The gene encoding the immunogenic protein MPT64 found in culture filtrates of Mycobacterium tuberculosis H37Rv was expressed in Escherichia coli K-12 and purified as a recombinant protein. The purified recombinant MPT64 elicited delayed-type hypersensitivity (DTH) in outbred guinea pigs sensitized with Mycobacterium bovis BCG Tokyo. The skin reactions were comparable to those obtained with native MPT64. No skin reactions were obsd. when either recombinant MPT64 or native MPT64 was used in guinea pigs sensitized with M. bovis BCG Danish 1331. Amino- and carboxy-terminal deletion mutants of MPT64 were purified as fusion proteins for the mapping of DTH-inducing epitopes on recombinant MPT64 by use of the guinea pig skin test model. The part of the mol. responsible for the biol. activity was located at the carboxy-terminal end. Further studies with overlapping synthetic peptides have pinpointed the biol. activity at a single DTH-inducing epitope consisting of 15 residues between amino acids Gly-173 and Ala-187. Screening by PCR of 56 clin. isolates of M. tuberculosis from Danish and Tanzanian patients demonstrated the presence of mpt64 in all of the strains. These results point to MPT64 as a possible candidate for a skin test reagent specific for diagnosis of human tuberculosis.

L16 ANSWER 18 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:678371 HCAPLUS  
 DOCUMENT NUMBER: 121:278371  
 TITLE: Characterization of a linear epitope on Chlamydia trachomatis serovar L2 DnaK-like protein  
 AUTHOR(S): Birkelund, Svend; Larsen, Bente; **Holm, Arne**;  
 Lundemose, Anker G.; Christiansen, Gunna  
 CORPORATE SOURCE: Inst. Med. Microbiol., Univ. Aarhus, Aarhus, DK-8000, Den.  
 SOURCE: Infect. Immun. (1994), 62(5), 2051-7  
 CODEN: INFIBR; ISSN: 0019-9567  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB A cytoplasmic 75-kDa immunogen from Chlamydia trachomatis serovar L2 has previously been characterized as being similar to the Escherichia coli heat shock protein DnaK. We have localized a linear epitope for one monoclonal antibody specific for C. trachomatis DnaK. By use of a recombinant DNA technique, the epitope was limited to 14 amino acids. With synthetic peptides, the epitope was further limited to eight amino acids. Six of these amino acids are conserved in bovine HSP70, which has a known three-dimensional structure. The amino acid sequence homologous to the epitope is located in a linear part of the HSP70 mol. known as connect II.

L16 ANSWER 19 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:677739 HCAPLUS  
 DOCUMENT NUMBER: 121:277739  
 TITLE: A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human

and murine tumors  
 AUTHOR(S): Solberg, Helene; Roemer, John; Brunner, Nils;  
**Holm, Arne**; Sidenius, Nicolai; Danoe, Keld;  
 Hoeyer-Hansen, Gunilla  
 CORPORATE SOURCE: Finsen Laboratory, Rigshospitalet, Copenhagen,  
 DK-2100, Den.  
 SOURCE: Int. J. Cancer (1994), 58(6), 877-81  
 CODEN: IJCNAW; ISSN: 0020-7136  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB It was recently found that urokinase-type plasminogen activator (uPA) is involved in the cleavage of its receptor (uPAR) on cultured cells, thereby releasing one of the receptor's 3 domains (the **ligand** binding domain 1) and leaving the 2 others [uPAR(2 + 3)] anchored to the cell surface. With monoclonal antibodies (MAbs) we have now identified human uPAR(2 + 3) in lysates of invasive human MDA-MB-231 mammary carcinomas xenografted into nude mice. The prodn. of peptide antibodies recognizing different domains of murine uPAR made it possible to identify a similar cleaved form of uPAR, murine uPAR(2 + 3), in exts. of primary Lewis lung carcinomas. Cleavage of uPAR also occurs in cultured MDA-MB-231 cells and Lewis lung carcinoma cells. This cleavage is inhibited by anticatalytic antibodies to either human or murine uPA, resp., indicating that it is catalyzed by either uPA or plasmin generated by uPA. The amt. of uPAR(2 + 3) may therefore be directly related to the activity of the uPA system and it is possible that the level of uPAR(2 + 3) in cancer tissue may prove to be a stronger prognostic parameter than the levels of either full-length uPAR or uPA.

L16 ANSWER 20 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:241931 HCAPLUS  
 DOCUMENT NUMBER: 120:241931  
 TITLE: A quantitative assay to measure the interaction  
 between immunogenic peptides and purified class I  
 major histocompatibility complex molecules  
 AUTHOR(S): Olsen, Anna Catharina; Pedersen, Lars Oestergaard;  
 Hansen, Anette Stryhn; Nissen, Mogens Holst; Olsen,  
 Marianne; Hansen, Paul Robert; **Holm, Arne**;  
 Buus, Soeren  
 CORPORATE SOURCE: Med. Fac., Univ. Copenhagen, Copenhagen, DK-2200, Den.  
 SOURCE: Eur. J. Immunol. (1994), 24(2), 385-92  
 CODEN: EJIMAF; ISSN: 0014-2980  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB A direct and sensitive biochem. assay to measure the interaction in soln. between peptides and affinity-purified major histocompatibility complex (MHC) class I mols. has been generated. Specific binding reflecting the known class I restriction of cytotoxic T cells responses was obtained. Adding an excess of .beta.2-microglobulin (.beta.2m) significantly increased the rate of peptide assocn., but it did not affect the rate of dissocn. Binding was complicated by a rapid and apparently irreversible loss of functional MHC class I at 37.degree.C which might limit the life span of empty MHC class I, thereby preventing the inadvertent exchange of peptides at the target cell surface. All class I mols. tested bound peptides of the canonical octameric to nonameric length. However, one class I mol., Kk, also bound peptides which were much longer, suggesting that the preference of class I mols. for short epitopes is not abs. and may be caused by factors other than the peptide-MHC class I binding event itself.

L16 ANSWER 21 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:49430 HCAPLUS  
 DOCUMENT NUMBER: 120:49430  
 TITLE: Peptide dot immunoassay and immunoblotting:

electroblotting from aluminum thin-layer chromatography plates and isoelectric focusing gels to activated nitrocellulose

AUTHOR(S): Lauritzen, Edgar; Masson, Mar; Rubin, Inger; Bjerrum, Ole J.; **Holm, Arne**

CORPORATE SOURCE: Dep. Virol., Statens Seruminst., Copenhagen, DK-2300, Den.

SOURCE: Electrophoresis (Weinheim, Fed. Repub. Ger.) (1993), 14(9), 852-9  
CODEN: ELCTDN; ISSN: 0173-0835

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Nitrocellulose membrane was preactivated with divinyl sulfone, and a spacer of 1,6-diaminohexane was coupled to the membrane which was functionalized by glutaraldehyde, leaving a reactive carbonyl group. The peptides were coupled to the carbonyl by the side chain and terminal amino groups. The octa-peptide angiotensin II (sequence: DRVYIHPF) and peptide analogs contg. 6-10 amino acid residues were dotted directly onto the matrix at 45.degree. for 15 min and detected by specific antisera, which were raised in rabbits against angiotensin I and II, resp. They were visualized by peroxidase-coupled anti-rabbit IgG antibodies. The detection limit for synthetic angiotensin II was 500 fg per cm<sup>2</sup> (= 500 amol per cm<sup>2</sup>) and for the decapeptide angiotensin I (sequence: DRVYIHPFHL) it was 500 pg per cm<sup>2</sup> (= 400 fmol per cm<sup>2</sup>). Sepn. of synthetic angiotensin analogs by high performance thin-layer chromatog. on silica coated aluminum plates was followed by electroblotting onto activated nitrocellulose and detection with specific antibodies, showing a sensitivity of 100 fg and 1 pg for angiotensin II and angiotensin I, resp. Isoelec. focusing in agarose using Ampholine carrier ampholytes and immunoblotting with specific antisera displayed a lower sensitivity for angiotensin II and angiotensin I of 2 ng and 20 ng, resp. The isoelec. focusing and immunoblotting technique was applied for sepn. of angiotensin I and II and related peptides in serum, where synthetic angiotensin I was degraded in the presence of 1 mM phenylmethylsulfonyl fluoride and 10 mM EDTA. The versatility of dot immunobinding on activated nitrocellulose was shown with two sera from patients infected with human immunodeficiency virus, HIV-1 and HIV-2, by using pH 10.2 in incubation media, resulting in a low background. These sera were bound specifically to either one of the closely related HIV-1 and HIV-2 peptide **antigens** from the two viruses.

L16 ANSWER 22 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:6323 HCAPLUS

DOCUMENT NUMBER: 120:6323

TITLE: Chemical activation of nitrocellulose membranes for peptide **antigen**-antibody binding studies: direct substitution of the nitrate group with diaminoalkane

AUTHOR(S): Masson, Mar; Lauritzen, Edgar; **Holm, Arne**

CORPORATE SOURCE: H.C Inst., Univ. Copenhagen, Copenhagen, Den.

SOURCE: Electrophoresis (Weinheim, Fed. Repub. Ger.) (1993), 14(9), 860-5  
CODEN: ELCTDN; ISSN: 0173-0835

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A method to covalently link peptide and proteins, through a diaminoalkane spacer to nitrocellulose membrane was developed for immunochem. applications. Initially the nitrocellulose membrane was modified by covalent incorporation of diaminoalkane spacers without any prior activation. The incorporation was shown primarily to involve .alpha.-elimination of the nitrate groups, and an imine was formed between the carbonyl group on the membrane and the diaminoalkane. The rate of incorporation increased exponentially with the length of the diaminoalkane

as detd. by a ninhydrin colorimetric reaction, which was developed for the study. More than 200 nmole diamine per mg nitrocellulose could be incorporated, but less than 11 nmol/mg (63 nmol/cm<sup>2</sup>) was chosen in order to retain the strength of the membrane. The primary amino groups of the modified membrane was glutaraldehyde activated and the octapeptide, angiotensin II, was covalently bound. A dot immunoassay was performed where specific anti-angiotensin II antibodies reacted with the peptide and was visualized by peroxidase coupled secondary antibodies. The results were quantified by video densitometry above 0.005 .mu.g AII per cm<sup>2</sup>. The immunoassay showed improved detection of the peptide on the activated as compared to unactivated membrane as well as increased retention of radiolabeled [125]angiotensin II.

L16 ANSWER 23 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1993:99951 HCAPLUS

DOCUMENT NUMBER: 118:99951

TITLE: Identification of murine T-cell epitopes on the S4 subunit of pertussis toxin

AUTHOR(S): Petersen, Jesper W.; **Holm, Arne**; Ibsen, Per H.; Hasloev, Kaare; Heron, Iver

CORPORATE SOURCE: Res. Cnet. Med. Biotechnol., Statens Seruminst., Copenhagen, DK-2300, Den.

SOURCE: Infect. Immun. (1993), 61(1), 56-63  
CODEN: INFIBR; ISSN: 0019-9567

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The aim of the present study was to identify murine T-cell epitopes on pertussis toxin subunit S4. Six mouse strains with 5 different haplotypes at the H-2 locus were immunized with the pertussis toxin B oligomer. Lymph node lymphocytes were isolated and stimulated in an in vitro proliferation assay with pertussis toxin components and 11 overlapping synthetic peptides synthesized on the basis of the primary sequence of S4. In vitro proliferative responses to the synthetic peptides revealed the presence of 4 distinct murine T-cell epitopes on subunit S4. The recognition of the peptides was major histocompatibility complex-restricted. Immunizing 4 of the 6 mouse strains with the synthetic peptides showed that the peptides which were demonstrated to contain T-cell epitopes following immunization with the B oligomer were able to induce proliferative responses to detoxified pertussis toxin and pertussis toxin components contg. subunit S4. One of the identified murine T-cell epitopes corresponded to one of the major human T-cell epitopes previously identified on subunit S4. It is hoped that this murine model system will facilitate the development of a synthetic immunogen mimicking the protective properties of pertussis toxin.

L16 ANSWER 24 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1992:6957 HCAPLUS

DOCUMENT NUMBER: 116:6957

TITLE: Solid phase peptide synthesis of selectively phosphorylated peptides

AUTHOR(S): Staerkaer, Gunnar; Jakobsen, Mogens H.; Olsen, Carl Erik; **Holm, Arne**

CORPORATE SOURCE: H. C. Oersted Inst., Univ. Copenhagen, Copenhagen, DK-2100, Den.

SOURCE: Tetrahedron Lett. (1991), 32(39), 5389-92  
CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal

LANGUAGE: English

AB An efficient, selective, solid-phase synthesis of phosphopeptides contg. a multiplicity of hydroxy-contg. amino acids is described. The peptide was **assembled** on the solid support using 9-fluorenylmethoxycarbonyl (Fmoc) amino acid active esters without side-chain protection for serine and tyrosine. Phosphorylation was carried out with Et<sub>2</sub>NP(OCMe<sub>3</sub>)<sub>2</sub> and

1H-tetrazole, followed by oxidn. with Me<sub>3</sub>COOH. After simultaneous deprotection and cleavage, the phosphopeptide H-Ala-Tyr(PO<sub>3</sub>H<sub>2</sub>)-Ala-Ser(PO<sub>3</sub>H<sub>2</sub>)-Ala-OH was obtained in high yield with >90% phosphorylation on both residues.

L16 ANSWER 25 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1991:78092 HCAPLUS

DOCUMENT NUMBER: 114:78092

TITLE: Covalently linked peptides for enzyme-linked immunosorbent assay

AUTHOR(S): Soendergaard-Andersen, Jan; Lauritzen, Edgar; Lind, Klaus; **Holm, Arne**

CORPORATE SOURCE: Res. Cent. Med. Biotechnol., Statens Seruminst., Copenhagen, DK-2300, Den.

SOURCE: J. Immunol. Methods (1990), 131(1), 99-104

CODEN: JIMMBG; ISSN: 0022-1759

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A general method is described, by which synthetic peptides are covalently linked via their carboxyl group to microtiter plates (CovaLink) for ELISA. Peptides were coupled to the microtiter plates using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide. Plates were prepd. by this method with an angiotensin II peptide and with an HIV-2 peptide and attachment detected by rabbit anti-angiotensin serum and with a pos. serum from an HIV-2-infected patient, resp., using the common ELISA procedure in the last steps. The method is simple to perform, it constitutes an alternative to the common ELISA method, and eliminates the risk of inadvertent loss of peptide during the procedure. The method is highly reproducible and has a high sensitivity. It may be used for either **antigen** or antibody detection.

L16 ANSWER 26 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1991:17616 HCAPLUS

DOCUMENT NUMBER: 114:17616

TITLE: Dot immunobinding and immunoblotting of picogram and nanogram quantities of small peptides on activated nitrocellulose

AUTHOR(S): Lauritzen, Edgar; Masson, Mar; Rubin, Inger; **Holm, Arne**

CORPORATE SOURCE: Virol. Dep., Statens Seruminst., Copenhagen, DK-2300, Den.

SOURCE: J. Immunol. Methods (1990), 131(2), 257-67

CODEN: JIMMBG; ISSN: 0022-1759

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Nitrocellulose was activated with divinyl sulfone, a spacer of ethylenediamine, and glutaraldehyde. The aldehyde groups on the activated nitrocellulose, Nit-CHO, were stable through 1 mo at 4.degree.. Peptides were attached to the membrane by reaction of the amino group with the free carbonyl, forming peptide bonds. The decapeptide angiotensin I (AI), the octapeptide angiotensin II (AII), angiotensin analogs, and Met- and Leu-enkephalin (Met-E and Leu-E) were tested on the membranes with specific rabbit antibodies (sRaAb) against the peptides, and visualized by horseradish peroxidase conjugated anti-rabbit antibody (HRP-anti-RaAb). With this technique AI and AII could be detected with sensitivities of 500 pg/cm<sup>2</sup> and 20 pg/cm<sup>2</sup>, resp. Substitution of Ala<sub>7</sub> for Pro<sub>7</sub> in AI and AII caused a reduced binding of anti-AI and anti-AII antisera, resp., and it completely abolished crossreactivity of anti-AI with Ala<sub>7</sub>-AII as well as of anti-AII with Ala<sub>7</sub>-AI. Peptides from the gp41 and gp36 **antigens** corresponding to the sequence aa596-618 of the human immunodeficiency viruses type 1 and 2, HIV-1 and HIV-2, were tested on Nit-CHO with 2 human sera from infected patients. The serol. reactions were specific for both the HIV-1 and HIV-2 peptide, resp. This indicated

that the technique could be exploited for serol. testing of humans. Sepn. of peptides by high performance thin layer chromatog. (HPTLC) and identification by immunoblotting was demonstrated with angiotensin analogs. After sepn. by HPTLC on silica aluminum plates the peptides were electrotransferred by semidry electroblotting on Nit-CHO, followed by specific antibody overlays and developed as for the dot immunobinding technique. This combined method enabled differentiation between closely related peptide analogs and it improved the sensitivity of peptide detection 100-1000 fold as compared to visualization by quenched fluorescence on chromatog. plates.

L16 ANSWER 27 OF 27 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1990:176538 HCAPLUS

DOCUMENT NUMBER: 112:176538

TITLE: The T-lymphocyte proliferative response to synthetic peptide **antigens** of defined secondary structure

AUTHOR(S): Mouritsen, Soeren; Meldal, M.; Rubin, B.; Holm, A.; Werdelin, O.

CORPORATE SOURCE: Inst. Exp. Immunol., Univ. Copenhagen, Copenhagen, DK-2100, Den.

SOURCE: Scand. J. Immunol. (1989), 30(6), 723-30  
CODEN: SJIMAX; ISSN: 0300-9475

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Immunodominant sites in proteins recognized by T lymphocytes are segments consisting of at least 7-8 amino acids. It has previously been proposed that these sites in proteins are .alpha.-helical and amphipathic structures. Here, the authors synthesized and investigated the immunogenicity of three synthetic peptides (MP7, MP8, and MP9), each consisting of the same 15 amino acids, but differing with respect to sequence. Based on information anal. and CD measurements, MP7 has an .alpha.-helical secondary structure and based on previously assigned hydrophilicity indexes, was also strongly longitudinally amphipathic. MP8 also was conformed as an .alpha.-helix, but was amphipathic in the sense that the N-terminal half of the mol. was hydrophilic and the C-terminal half hydrophobic. MP9 had neither an amphipathic nor an .alpha.-helical structure. All three peptides were immunogenic in some strains of mice but none was immunogenic in all strains. This supports other studies concluding that amphipathicity per se is neither a necessary nor sufficient requirement for immunogenicity of a peptide. However, these data suggest that longitudinally amphipathic .alpha.-helical peptides may function better as T-cell determinants than the other peptides investigated.

=>

=>

=> s ((17 or 18 or 19 or 110 or 111) and 12) not (112 or 19 or 110 or 114 or 115 or 116)  
L17 0 ((L7 OR L8 OR L9 OR L10 OR L11) AND L2) NOT (L12 OR L9 OR L10  
OR L14 OR L15 OR L16)